



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

31 MAR 2000


THIS PAGE BLANK (REV)

15 APR 1999

1/77

Patents Act 1977 15 APR 1999

(Rule 16)



16APR99 E440397-1 D02882
P01/7700 0.00 - 9908670.4

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1.	Your reference	SCB/NLW/52456/000		
2.	Patent application number (The Patent Office will fill in this part)	9908670.4		
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	DEVGEN nv Technologiepark Zwijnaarde 9 B-9052 Zwijnaarde Belgium Patents ADP number (if you know it) If the applicant is a corporate body, give the country/state of its incorporation		
		Belgium 07454911002		
4.	Title of the invention	COMPOUND SCREENING METHOD		
5.	Name of your agent (if you have one) "Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode) Patents ADP number (if you know it)	BOULT WADE TENNANT 27 FURNIVAL STREET LONDON EC4A 1PQ 42001		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day/month/year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)	
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	YES		

Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 65

Claim(s) 21

Abstract

Drawing(s) 14

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (Please specify)

11

I/We request the grant of a patent on the basis of this application.

Signature

Date

Basil Whitehead 15 April 1999

12.

Name and daytime telephone number of person to contact in the United Kingdom

Nina L White
0171 430 7500

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Compound screening method

The invention relates to the field of pharmacology and in particular to the screening of chemical substances with potential pharmacological activity using nematode worms such as *Caenorhabditis elegans*. Specifically, the invention relates to methods adapted for high-throughput screening which are performed in a multi-well plate format.

Caenorhabditis elegans is a nematode worm which occurs naturally in the soil but can be grown easily in the laboratory on nutrient agar or in liquid nutrient broth inoculated with bacteria, preferably *E. coli*, on which it feeds. Each worm grows from an embryo to an adult worm of about 1mm long in three days or so. As it is fully transparent at all stages in its life, cell divisions, migrations and differentiation can be seen in live animals.

Furthermore, although its anatomy is simple its somatic cells represent most major differentiated tissue types including muscles, neurons, intestine and epidermis. Accordingly, differences in phenotype which represent a departure from that of a wild-type worm are relatively easily observed, either directly by microscopy or by using selective staining procedures.

These characteristics of *C. elegans* make it an extremely useful tool in the drug discovery process. In particular, *C. elegans* may be used in the development of compound screens, useful in the identification of potential candidate drugs, in which worms are exposed to the compound under test and any resultant phenotypic and/or behavioural changes are recorded.

The possibility that *C. elegans* might be useful

for establishing interactions between external molecules and specific genes by comparison of *C. elegans* phenotypes which are generated by exposure to particular compounds and by selected mutations is considered by Rand and Johnson in Methods of Cell Biology, Chapter 8, volume 84, *Caenorhabditis elegans: Modern Biological analysis of an Organism* Ed. Epstein and Shakes, Academic Press, 1995 and J. Ahringer in Curr. Op. in Gen. and Dev. 7, 1997, 410-415.

Rand and Johnson in particular describe compound screening assays in which varying concentrations of the compound to be tested are added to nutrient agar or broth which is subsequently seeded with bacteria and then inoculated with worms. Any phenotypic changes in the worm as a result of exposure to the compound are then observed.

Although the nematode, and in particular *C. elegans*, is proving a powerful and efficient tool in the identification or discovery of pharmacologically active molecules, the presently known techniques for compound screening do not readily lend themselves to high throughput screening. This is largely because the known assay techniques rely on visual inspection of worms exposed to the compound under test in order to determine whether the compound has an effect on the phenotype of the worms. Consequently, even if an assay were to be performed in the multi-well assay format necessary for high throughput screening it would be necessary to score each individual well by eye in order to determine the outcome of the assay.

There is thus a need for reliable and reproducible screening methods using live *C. elegans* which do not require scoring by visual inspection and are therefore more suitable for use in automated high

throughput screening. The availability of such screening methods would dramatically increase the usefulness of *C. elegans* as a screening tool, enabling researchers to exploit the enormous potential of *C. elegans* as a whole animal system for drug discovery and development.

Accordingly, in a first aspect the invention provides a method of identifying chemical substances which have potential pharmacological activity using nematode worms, which method comprises the steps of:

(a) dispensing substantially equal numbers of nematode worms into each of the wells of a multi-well assay plate;

(b) contacting the nematode worms with a sample of a chemical substance;

(c) detecting a signal indicating phenotypic, physiological, behavioural or biochemical changes in the nematode worms using non-visual detection means.

In a second aspect the invention provides a method of determining the mode of action of a chemical substance using nematode worms, which method comprises the steps of:

(a) dispensing substantially equal numbers of a panel of different mutant nematode worms into each of the wells of a multi-well assay plate;

(b) contacting the nematode worms with the chemical substance; and

(c) detecting a signal indicating phenotypic, physiological, behavioural or biochemical changes in the nematode worms using non-visual detection means.

In a third aspect the invention provides a method of identifying further components of the biochemical pathway on which a compound having a defined effect on nematode worms acts, which method comprises the steps of:

(a) subjecting a population of nematode worms to random mutagenesis;

(b) dispensing one mutagenized F1 nematode worm into each of the wells of a multi-well assay plate;

5 (c) allowing the F1 nematode worms to generate F2 offspring;

(d) contacting the nematode worms with the compound; and

10 (e) detecting a signal indicating phenotypic, physiological, behavioural or biochemical changes in the nematode worms using non-visual detection means.

In a fourth aspect the invention provides a method of identifying chemical substances which modulate the effect of a first compound, which
15 compound has a defined effect on nematode worms, which method comprises the steps of:

(a) dispensing substantially equal numbers of nematode worms into each of the wells of a multi-well assay plate;

20 (b) contacting the nematode worms with the first compound;

(c) contacting the nematode worms with a further chemical substance; and

25 (d) detecting a signal indicating phenotypic, physiological, behavioural or biochemical changes in the nematode worms using non-visual detection means.

The methods of the invention are all performed in a multi-well plate format and are therefore particularly suitable for use in mid-to-high
30 throughput screening. In a preferred embodiment, the multi-well plates have 96 wells, but the invention is also applicable to multi-well plates with another number of wells, which include but is not restricted to plates with 6, 12, 24, 384, 864 or 1536 wells.

35 As with all the screening methods described

herein the above-described methods are preferably performed using nematode worms from the genus *Caenorhabditis*, most preferably *C. elegans* or *C. briggsae*.

5 All of the methods of the invention require the detection of a signal which indicates phenotypic, physiological, behavioural or biochemical changes occurring in the nematode worms in the presence of the compound under test. It is an essential feature of
10 the methods of this invention that this signal (also referred to as the read-out) is detected using a non-visual detection means. As used herein the term "non-visual detection means" refers to any means of detecting a signal which does not require visual
15 inspection by the human eye.

The use of a non-visual detection system represents a major advantage over previously known screening methods using which require visual inspection of the nematodes by eye in order to detect
20 gross phenotypic or behavioural changes.

The signal generated as a result of phenotypic, physiological, behavioural or biochemical changes in the nematode worms can be of various types including, for example, a fluorescent, luminescent or
25 colorimetric signal generated in the nematode worms themselves or a change in optical density in a whole suspension of worms.

In one embodiment of the methods a signal is generated by a marker molecule which is added to the
30 worms following contact with the chemical substance under test. The marker molecule is taken up by the worms and the activity of the chemical substance on the nematode worms can then be monitored either directly or indirectly by detecting signal resulting
35 from a change in the properties of the marker molecule

as a result of phenotypic, physiological, behavioural or biochemical changes in the worms.

There are various ways in which the worms can take up the marker molecule. For example, worms may take up the marker as a result of the action of a chemical substance under test. Another possibility is that the worms can be pre-loaded with the marker molecule prior to the addition of chemical substance or the marker molecule can be delivered via the media in which the worms are cultured or via bacteria or other food particles on which the worms feed.

Alternatively, the marker molecule can be a genetically encoded marker which is expressed in cells of the nematode worms themselves. Routine methods for the construction of transgenic *C. elegans* are well known in the art and with the use of appropriate promoter sequences transgenic *C. elegans* can be constructed which express a genetically encoded marker molecule in all cells, in a particular tissue or in one or more specified cell types. Suitable genetically encoded marker molecules include autonomous fluorescent proteins (AFP) such as green fluorescent protein (GFP) and blue fluorescent protein (BFP), aequorin, alkaline phosphatase, luciferase, β -glucuronidase, β -lactamase and β -galactosidase.

The marker molecule can also be added to the nematodes as a 'precursor' molecule which can undergo chemical changes in the nematodes as a result of the biochemical activity of the nematode. This biochemical activity on the precursor changes its properties resulting in the generation of a signal which can be measured. A typical example of this system is the use of a precursor marker molecule which can be cleaved by enzymes present in the gut of the nematode worms to generate a marker molecule with a

detectable property such as, for example, fluorescence. Examples of such precursor marker molecules include calcein-AM , fluorescein diacetate (FDA) and BCECF-AM which are cleaved by esterases, alkaline phosphatase substrates such as fluorescein diphosphate and AMPPD, aminopeptidase substrates such as CMB-leu, and glucuronidase substrates such as X-gluc.

In order to assist in the measurement of a signal generated using a marker molecule, fluorescence quenchers or luminescence quenchers may be used. For example, a quencher could be added to the medium in order to quench any background fluorescence in the medium, this may make it easier to visualise a fluorescence signal from the gut of the nematodes.

Suitable non-visual detection means include multi-well plate readers, also known as microtiter plate readers or elisa plate readers. The use of microtiter plate readers facilitates high throughput screening to select for active chemical substances with potential pharmacological activity. Suitable multi-well plate readers are commonly used in the art and are available commercially. Such plate readers can be used with a wide range of detection methods including fluorescence detection, luminescent detection, colorimetric detection, spectrophotometric detection, immunochemical detection, radiation detection and optical density detection.

The advantage of multi-well plate readers is that they can be used to make quantitative measurements of the signal generated as a result of the activity of the chemical substances on the nematode worms. The ability to make quantitative measurements means that it is possible to construct quantitative dose response curves of the activity of a chemical compound on the

nematodes. Using these dose response curves one can determine the IC50 and ED50 of compounds in nematodes such as *C. elegans*, and hence determine optimal concentrations. Furthermore, the dose response curves enable the determination of any toxic effects of the compound and may also give an indication of possible secondary targets and side-effects of the compound.

Non-visual detection systems other than multi-well plate readers can also be used in the methods of the invention. An example of such a detection system is based on a 'worm dispenser apparatus' which is commercially available from Union Biometrica, Inc, Somerville, MA, USA. Such a worm dispenser apparatus has properties analogous to flow cytometers such as fluorescence activated cell scanning and sorting devices (FACS). Such a device, designated a nematode flow meter, can be the nematode FACS analogue, described as fluorescence activated nematode scanning and sorting device (FANS). The FANS device enables the measurement of nematode properties, such as size, optical density, fluorescence, and luminescence. For screening assays to be performed with a small number of nematodes or for assays that give a faint signal, or for assays for which the presence of food can be a disadvantage in the measurement of the signal, a FANS is a preferred detection instrument. However, the use of a FANS is not limited to these experimental conditions, FANS could be generally used for all the screening methods described herein.

A screening method using a FANS device is quite analogous to the screening method described for the multi-well plate reader. In short, worms are contacted with the chemical substances with or without the addition of a marker molecule. After the appropriate time, the multi-well plates are submitted to the FANS apparatus and in a fully automated

procedure the worms are analysed well-by-well for features such as overall size, fluorescence, luminescence or optical density. The desired features are then scored. With the use of the FANS device
5 screens can also be performed quantitatively.

In order to generate quantitative results using the methods of the invention it may be important to ensure that substantially equal numbers of individual nematodes are added to each of the wells. The precise
10 number of worms added to the wells may vary depending upon the type of screen being performed and the required sensitivity. In all plate formats, including 96 well plates, it is preferred to use 1 to 100 worms per well, more preferably 10 to 80 worms per well and
15 most preferably 40 worms per well.

Various methods can be used to ensure that substantially equal numbers of worms are added to each of the wells. One way in which this can be achieved is by taking worms cultured according to the standard
20 procedures known to those skilled in the art in solid or liquid media and re-suspending the worms in a viscous solution to form a homogeneous suspension. The viscosity of the solution maintains an even distribution of worms in the suspension, thus
25 substantially equal numbers of worms can be dispensed by adding equal volumes of the homogeneous worm suspension to each of the wells. Suitable viscous solutions include a solution containing a low concentration of a polymer material (e.g. 0.25% low
30 melting point agarose), glycerol etc.

As an alternative to the above-described approach an equal distribution of worms over the wells of the multi-well plate can be achieved using a worm dispensing device, such as that developed by Union
35 Biometrica, Inc. The worm dispenser can be programmed to add a set number of worms to each of the wells of

the plate. In addition, it can be used to select worms in such a way that only hermaphrodites or males or dauers are dispensed and it can also select on the basis of size so that specifically eggs, L1, L2, L3,
5 L4 or adult worms are dispensed.

All of the screening methods described herein can be performed using various kinds of *C. elegans*, including wild-type worms, selected mutants, transgenic worms and humanized worms. The transgenic
10 strains can be strains expressing a transgene in the whole organism, or in a part of the organism, in a single tissue, in a sub-set of cell types, in a single cell type or even in one cell of the organism. The mutant worms may carry a mutation in a single gene or
15 in two or more different genes.

Standard methods for culturing nematodes are described in Methods in Cell biology Vol. 48, 1995, ed. by Epstein and Shakes, Academic press. Standard methods are known for creating mutant worms with
20 mutations in selected *C. elegans* genes, for example see J. Sutton and J. Hodgkin in "The Nematode *Caenorhabditis elegans*", Ed. by William B. Wood and the Community of *C. elegans* Researchers CSHL, 1988 594-595; Zwaal et al, "Target - Selected Gene
25 Inactivation in *Caenorhabditis elegans* by using a Frozen Transposon Insertion Mutant Bank" 1993, Proc. Natl. Acad. Sci. USA 90 pp 7431 -7435; Fire et al, Potent and Specific Genetic Interference by Double-Stranded RNA in *C. elegans* 1998, Nature 391, 860-811.
30 A population of worms can be subjected to random mutagenesis by using EMS, TMP-UV or radiation (Methods in Cell Biology, Vol 48, *ibid*). Several selection rounds of PCR could then be performed to select a mutant worm with a deletion in a desired gene.

35 In one embodiment the methods of the invention

are performed using transgenic *C. elegans* expressing a transgene which comprises a 'toxic gene'. In this context the term 'toxic gene' encompasses any nucleic acid sequence which encodes a protein which is toxic to the cell. Suitable examples include nucleic acid encoding ataxin, alpha-synuclein, ubiquitin, the tau gene product, the Huntington's gene product, the best macular dystrophy gene product, the age-related macular dystrophy product or the unc-53 gene product. 'Toxic genes' encoding proteins involved in apoptosis or necrosis could also be used with equivalent effect.

Using appropriate tissue-specific or cell type-specific promoters transgenic *C. elegans* can be constructed which express one or more toxic genes in a single tissue, in a subset of cell types, in a single cell type or even in a single cell, for example a single neuron. Expression of the toxic gene will generally result in abnormality/malfunction of the cells and tissues expressing the toxic gene. Many suitable tissue-, cell type- or developmentally-specific promoters are known for use in *C. elegans*.

All of the screening methods described herein can also be performed using synchronized worm cultures. Synchronized worms are worms that are in the same growth stage. The various growth stages of nematode worms such as *C. elegans* are eggs, the L1 stage, L2 stage, L3 stage, L4 stage and adult stage. Furthermore, in a preferred embodiment of the invention, the synchronized nematode worms are of a specific sex. The synchronized cultures can be hermaphrodites or males or nematodes in special larval stage, designated dauers.

Techniques suitable for use in generating the various synchronized cultures are known in the art, see for example Methods in Cell Biology, vol 48, *ibid*.

The main population of a standard *C. elegans* culture consists of hermaphrodite worms, so it does not require special techniques to generate synchronized hermaphrodite nematodes in different growth stages.

5 To generate male worms, several techniques have been described in the literature. *C. elegans* cultures that are enriched or consist exclusively of male worms, have been described in *C. elegans* II, ed, By Fiddle, Blumenthal, Meyer and Pries, 1997, CSHL press.

10 Strains for making enriched or pure male samples have been described by Johnathan Hodgkin, Worm breeder's gazette 15(5), 1999). To generate *C. elegans* dauers, several techniques have been described (*Elegans* II, *ibid*). Mainly, a temperature sensitive *daf-c* mutant
15 of *C. elegans* is used to generate dauers, although other possibilities exist such as *daf2-ts* mutants which produce 100% dauers at 25°C.

In a particular embodiment of the methods of the invention, the step of detecting a signal indicating
20 phenotypic, physiological, behavioural or biochemical changes in the nematode worms using non-visual detection means comprises detecting changes in the pharynx pumping rate of the nematode worms. These methods may be hereinafter be collectively referred to
25 as 'pharynx pumping assays'.

C. elegans feeds by taking in liquid containing its food (e.g. bacteria). It then spits out the liquid, crushes the food particles and internalises them into the gut lumen. This process is performed by
30 the muscles of the pharynx. The process of taking up liquid and subsequently spitting it out is called pharyngeal pumping or pharynx pumping.

Because the process of pharynx pumping involves both the muscles of the pharynx and also pharyngeal
35 neurons, measurement of the rate of pharynx pumping

can be exploited to provide a useful screen to identify chemical substances which have an effect on muscle and/or nerve activity.

5 The rate of pharynx pumping can be readily measured by detecting the accumulation of a marker molecules in the worm gut. If this is done using a multi-well plate reader then the assay can be performed rapidly and quantitatively.

10 In particular, the pharynx pumping rate may be measured by using a marker molecule precursor which is cleavable by enzymes present in the gut of the nematodes, as described above. Calcein-AM is particularly preferred for this purpose. Calcein-AM is an esterase substrate, and upon cleavage of
15 calcein-AM by esterases, calcein (a fluorescent molecule) is released. As esterases are present in the gut of nematodes such as *C. elegans*, the pharynx pumping rate can be measured indirectly by measuring calcein fluorescence.

20 In the examples given herein, calcein-AM has been used to measure the rate of pharynx pumping in *C. elegans* in the presence or absence of several chemical substances. These measurements can be performed in a quantitative high throughput way, allowing selection
25 for chemical substances that alter the pumping rate of the *C. elegans* pharynx. This method is not restricted to the use of calcein-AM and other precursor substrates could be used, such as:

With a fluorescent read out:

30 - Esterase substrates. Calcein-AM, FDA, BCECF-AM
-Alkaline phosphatase substrates: Fluorescein di phosphate FDP)

-Endoprotease; Aminopeptidase substrates: CMB-leu

With a luminescent read out:

35 -Alkaline phosphatase substrates: AMPPD

With a colour read out:

-Glucuronidase substrates: X-gluc

This list is not exclusive, marker molecule precursors can also be found or developed which are
5 cleavable by other enzymes present in the *C. elegans* gut, such as DNAses, ATPases, lipases, amylases, etc. Once such a marker precursor enters the gut, it is cleaved to release the detectable marker which can then be monitored. Thus, it is possible to measure the
10 rate of pharynx pumping indirectly by measuring the accumulation of a detectable marker molecule in the gut.

The pharynx pumping assays can also be performed using mutant *C. elegans* strains which have a
15 constitutively pumping pharynx or by using transgenic strains which also exhibit this phenotype. By using a wild-type strain or the constitutive pharynx pumping strain, it is possible to identify chemical substances that enhance, inhibit or modulate pumping rate,
20 respectively.

As the pharynx of the nematode *C. elegans* is a muscle and the pumping rate is mainly governed by some selected neurons, measuring changes in the pharynx pumping rate is a good tool to study neurotransmitter
25 signals and the stimulation of muscles. As the rate of pharynx pumping can be measured quantitatively and a method has been developed to screen for chemical substances which influence this pumping rate, the present invention is a method to screen and isolate
30 chemical substances with potential pharmacological activity.

Chemical substances that influence the pharynx pumping rate will most probably be substances that have an activity on general muscle biology, and/or on
35 neurotransmitter pathways. Examples of proteins which

can be the target of these chemical substances are neurotransmitter receptors such as muscarinic receptors, glutamate receptors, hormone receptors and 5-HT receptors, cannabinoid receptors, adrenergic receptors, dopaminergic receptors, opioid receptors, GABA receptors, adenosine receptors, VIP receptors and nicotinic receptors, proteins involved in neurotransmitter synthesis, neurotransmitter release pathway proteins, G-protein coupled receptor proteins. Furthermore proteins for G-protein coupled second messenger pathways such as adenylate cyclase, protein kinase A, cAMP responsive element binding proteins, IP3, diacylglycerol, protein kinase C phospholipase A-D, phosphodiesterases, and proteins encoding for functions in gap junctions, ion channel proteins and ion pumps proteins are also potential targets for such chemical substances. Examples of such ion channels are sodium/calcium channel, calcium channel, sodium channel and chloride channels. In general, drugs or chemical substances that affect the pumping rate of the *C. elegans* pharynx and which are identified using the pharynx pumping screen will most probably be compounds that show the following activities:

- molecules that have influence on neurotransmitter molecules or that are precursors for the synthesis of a neurotransmitter,
- molecules that enhance, inhibit or modulate the synthesis of a neurotransmitter,
- molecules that have a function in the depletion of the transmitter,
- molecules that prevent or stimulate the release of the transmitter from the synaptic vesicles in the synaptic cleft,
- molecules that function as a receptor inhibitor or stimulator,
- molecules that mimic the transmitter molecules that

- function as conduction inhibitors or activators,
- molecules that function as an activator or inhibitor of the conduction blockade,
- molecules that prevent or stimulate the re-uptake of transmitter after firing of the neuron,
- molecules that function as a false transmitter (+/-),
- molecules that prevent or stimulate receptor clustering,
- molecules that act in novel pathways.

Thus, the pharynx pumping assays can be used to screen for a broad range of chemical substances with potential pharmacological activity that may have a therapeutic use as anti-psychotic, anti-depressant, anxiolytic, tranquillizer, anti-epileptic, muscle relaxant, sedative or hypnotic agents. The assays may also be used to identify chemical substances that may effect Parkinson's disease and Alzheimer's disease. Furthermore, anti-pruritic, anti-histaminic, and anti-convulsant drugs may also be isolated using the pharynx pumping assay.

The pharynx pumping assay may also be used to identify chemical substances which modulate the neurotransmitter pathways involving acetylcholine, dopamine, serotonin, glutamate, GABA and octopamine. This can be achieved by using selected mutant *C. elegans* which exhibit altered levels of one or more of the above-listed neurotransmitters.

With the pharynx pumping assay there is the potential to screen for 10 to 15 modes of action and for 2 to 6 neurotransmitter pathways and ion channels. As both activation as inhibition can be observed, this screening method will make it possible to screen for 40 to 180 targets in a single screen.

The pharynx pumping assay methodology can, in addition to the screens described above, be adapted

for use in determining the mode of action of a chemical substance, or to select for chemical substances which act on a specific target

5 In order to perform a screen to identify the mode of action of a compound substantially equal numbers of a panel of different defined mutant, transgenic or humanized nematodes are dispensed into the wells of a multi-well assay plate. A sample of the chemical substance under test is then added to
10 each of the wells and changes in the rate of pharynx pumping are detected as described above. For each of the mutant, transgenic or humanized strains the rate of pharynx pumping in the absence of any chemical substances is also scored. The pharynx pumping assay
15 can thus be used to identify chemicals which enhance or suppress the rate of pharynx pumping in a defined mutant, transgenic or humanized strain.

The examples given herein list several mutant and transgenic *C. elegans* strains which are useful in this
20 aspect of the invention. Mainly these mutants and transgenics relate to neurotransmitter synthesis, neurotransmitter signal transduction and ion channels. More specifically, examples of mutant, transgenic and humanized worms are given which relate to
25 neurotransmitter receptors such as muscarinic receptors, glutamate receptors, hormone receptors, 5-HT receptors, cannabinoid receptors, adrenergic receptors, dopaminergic receptors, opioid receptors, GABA receptors, adenosine receptors, VIP receptors and
30 nicotinic receptors, proteins involved in neurotransmitter synthesis, neurotransmitter release pathways and G-protein coupled receptor proteins, G-protein coupled second messenger pathways such as adenylate cyclase, protein kinase A, cAMP responsive
35 element binding proteins, IP3, diacylglycerol, protein

kinase C, phospholipase Q and proteins encoding for functions in gap junctions, ion channels proteins and ion pumps proteins. A non-exhaustive list of well known mutants which are suitable for use in this aspect of the invention is provided in the examples given herein.

Using such mutant, transgenic or humanized strains it is possible to screen for chemical substances which act on a specified target and thus identify a broad range of chemical substances that may have a therapeutic use as anti-psychotics, anti-depressants, anxiolytics, tranquillizers, anti-epileptics, muscle relaxants, sedatives or hypnotics, but the screen will also result in chemical substances that may have an effect on Parkinson's disease and Alzheimer's disease. Furthermore, anti-pruritic, anti-histaminic, and anti-convulsant drugs may be isolated. The transmitter pathway that maybe effected by chemical substances and hence may be detected by the assay are the pathways for acetylcholine, dopamine, serotonin, glutamate, GABA and octopamine.

These mutant, transgenic and humanized worms also allow the development of screens for chemical substances that have an activity in well-defined biochemical pathways. For example, it is possible to screen for compounds that rescue the phenotype of selected mutant *C. elegans* which carry a defined mutation in a known gene or compounds which enhance the phenotype of the selected mutant *C. elegans*.

In another embodiment of the invention the pharynx pumping assay methodology can be used to identify further components of the biochemical pathway on which a compound having a defined effect on nematode worms acts. Using this screen it is possible to identify genes that enhance, suppress or modulate the activity of a selected compound. The screen can be

done directly and rapidly as using multi-well plates thousands of worms can be screened at once.

First, a random pool of mutant worms is generated. Several techniques such as EMS mutagenesis, 5 TMP-UV mutagenesis and radiation mutagenesis have been described to generate mutant worms (Methods in Cell biology, Vol. 48, *ibid*). One mutagenized F1 nematode is then dispensed into each of the wells of the multi-well plate and the F2 generation are allowed to 10 produce offspring in the wells. A sample of a compound that has a known activity on the nematode worms is then added to the F2 worms. Changes in the pharynx pumping rate are then monitored as described above, for example using a marker molecule or a marker 15 molecule precursor.

Mutant worms are scored in which the effect of the compound on the pharynx pumping rate is suppressed, enhanced or modulated. These mutant worms will have mutations in one or more genes that are 20 affected by the compound. The mutated gene or genes can then be isolated using standard genetic and molecular biology techniques. These genes, and their corresponding proteins, are considered to be important genes and proteins of the affected pathway, and hence 25 are putative new targets for the further development of screens in the drug discovery process. As with all the methods described herein, this method is preferably performed using nematodes of the genus *Caenorhabditis*, most preferably *C. elegans*.

30 In still another embodiment of the invention the pharynx pumping assay methodology can also be used to screen for chemical substances that are enhancers, suppressors or modulators of a selected chemical compound having a defined effect on nematode worms.

35 In this assay worms are placed in multi-well plates with a compound that has known effect on the

pharynx pumping rate of nematode worms. A second chemical substance is then added to each of the wells and chemical substances which enhance, reduce or modulate the effect of the selected compound are identified by detecting changes in the pharynx pumping rate of the nematode worms using the methods described above. This method is useful to screen for chemical substances that are active in a selected biochemical pathway. The chemical substances thus isolated can be putative therapeutics, or can be considered as hits for further drug development.

In a still further embodiment of the pharynx pumping assay, the assay is performed using *C. elegans* which are transgenic, or mutant or humanized for the Sarco/endoplasmic reticulum calcium ATPase gene (SERCA) and/or for its regulators Phospholamban (PLB) and Sarcolipin (SLN). These genes are important for the regulation of the internal storage of calcium in the cell.

Chemical substances that alter the pumping rate of the pharynx in these mutant, transgenic or humanized worms are substances that modulate the activity of SERCA or PLB or SLN or that alter the interaction of SERCA-PLB or that alter the interaction of SERCA-SLN or that alter the activity of the SERCA pathway. Such chemical substances may be useful as therapeutics or may be hit compounds useful for further drug development in the area of cardiovascular diseases including hypertension, cardiac hypertrophy and cardiac failure, but also in the area of diabetes mellitus and in the area of skeletal muscle diseases including Brody disease.

In a still further embodiment of the pharynx pumping assay the assay may be performed using nematodes which exhibit aberrant pharynx morphology

and/or function.

The pharynx of the nematode consists of several cell types and all of these are required for the pharynx to function properly. In addition, pharynx
5 pumping is regulated by several neurons. The cells essential for pharyngeal morphology and pharyngeal function are the pharyngeal muscles, the pharyngeal epithelial cells, the pharyngeal glands and the pharyngeal neurons. If one of these cell types is
10 altered, degenerated or dysfunctional, the pharynx will have an aberrant morphology or an aberrant function which results in an altered pumping of the pharynx.

The examples given below list known *C. elegans*
15 mutants that exhibit an altered pumping rate as a result of an altered pharyngeal morphology. In addition, it is possible to generate *C. elegans* worms which exhibit a defect in one or more of the cell types required to maintain the morphology and/or
20 function of the *C. elegans* pharynx. This can be achieved by expressing 'toxic genes' in cells of the pharynx. In this context the term 'toxic genes' encompasses any nucleic acid sequence which encodes a protein which is toxic to the cell. Suitable examples
25 include nucleic acid encoding ataxin, alpha-synuclein, ubiquitin, the tau gene product, the Huntington's gene product, the best macular dystrophy gene product, the age-related macular dystrophy product or the unc-53 gene product. 'Toxic genes' encoding proteins
30 involved in apoptosis or necrosis could also be used with equivalent effect. Expression of the toxic genes in the pharynx or in particular cell types within the pharynx can be achieved using tissue-specific or cell type-specific promoters which are capable of directing
35 the appropriate expression pattern. For example, the

myo-2 promoter can be used to direct expression in the pharynx and the unc-129 promoter can be used to direct expression in the pharyngeal neurons. Other suitable promoters included the tropomyosin promoter tmy-1 and the daf-7 promoter. Expression of a toxic gene in one or more cell types of the pharynx or in the pharyngeal neurons will result in a changed morphology and/or function of the pharynx, and hence an alteration of the pharynx pumping rate. Interestingly, disruption of the ASI neuron by expression of a toxic gene under the control of the daf-7 promoter results in dauer formation. This is directly the result of a lack of insulin hence *C. elegans* in which the ASI neuron is disrupted can be used to perform screens which may be useful in relation to diabetes. These screens could be performed using the pharynx pumping assay read-out or alternatively the movement assay read-out described below (see example 12).

Mutant or transgenic worms which exhibit an altered pharynx pumping rate can be used to screen for chemical substances which further alter the pharynx pumping rate e.g. which rescue the mutant/transgenic phenotype or which enhance the mutant/transgenic phenotype. The chemical substances thus isolated may be useful as therapeutic agents or as hit compounds for further drug development in disease areas such as anti-depressants, anti-psychotics, anxiolytics, tranquillizers, anti-epileptics, muscle relaxants, sedatives, anti-migraine drugs, analgesics and hypnotics. Furthermore, by altering the nature of the toxic gene expressed in cells of the pharynx/pharyngeal neurons chemical substances will be isolated that are useful in the development of treatments for Parkinson's disease, Alzheimer's disease, Lewy body disease, Best macular dystrophy, age-related macular dystrophy and polyglutamine-

induced diseases such as Huntington's disease, Kennedy's disease and ataxia.

In a further embodiment of the invention the step of detecting a signal indicating a phenotypic, physiological, behavioural or biochemical changes in the nematode worms using non-visual detection means comprises detecting changes in the intracellular levels of ions, metabolites or secondary messengers in cells of the nematode worms.

In this particular embodiment of the invention, the activity of a chemical substance is not detected indirectly by measuring a signal from a marker molecule, but by measuring the activity of genetically encoded sensor whose properties are altered in the presence of specific ions, metabolites or secondary messengers. For example, changes in intracellular levels of Ca^{2+} can be detected using the genetically encoded calcium sensor molecules GFP-calmodulin or aequorin. GFP-calmodulin is known to be fluorescent in the presence of calcium ions. Thus, when intracellular calcium levels are low, no fluorescence can be detected but if the calcium levels increase calcium binds to the GFP-calmodulin causing a conformational change which results in a fluorescent molecule which can be detected, for example using a multi-well plate reader. Other genetically encoded sensor molecules could be used whose fluorescent or luminescent properties are altered in the presence of secondary messengers such as, for example, cAMP, diacylglycerol or inositol triphosphates (IP3).

Preferably this aspect of the invention is carried out using transgenic *C. elegans* which express the genetically encoded sensor in all cells, or in specific tissues, or in selected cells. This can be achieved with the use of tissue-specific or cell type-specific promoters with suitable activity. The method

can be performed using transgenic worms which express GFP-calmodulin in any cells/tissues of the nematode which are sensitive to calcium signalling, including cells of the pharynx, the vulva muscles, the body wall muscles and neurons. As in previous examples, the transgenic worm can be of wild-type genetic background, a mutant transgenic or a humanized strain.

As intracellular calcium levels in the cells of the pharynx are correlated with the pharynx pumping rate, the fluorescence detected in transgenic nematodes expressing GFP-calmodulin in these cells is an indication of the pharynx pumping rate and these transgenic worms can also be used to screen for chemical substances that influence the pumping rate of the pharynx.

In a still further embodiment of the invention, the step of detecting a signal indicating a phenotypic, physiological, behavioural or biochemical changes in the nematode worms using non-visual detection means comprises detecting changes in the movement behaviour of the nematode worms.

Nematode worms that are placed in liquid culture will move in such a way that they maintain a more or less even (or homogeneous) distribution throughout the culture. Nematode worms that are defective in movement will precipitate to the bottom in liquid culture. Due to this characteristic of nematode worms as result of their movement phenotype, it is possible to monitor and detect the difference between nematode worms that move and nematodes that do not move.

The movement of nematode worms is mainly the result of the action of the body wall muscles and is regulated by neuronal activity. Accordingly, screens based on detection of altered movement behaviour can be developed to identify chemical substances which may have an effect on muscle and/or neuronal activity.

Advanced multi-well plate readers are able to detect sub-regions of the wells of multi-well plates. By using these plate readers it is possible to take measurements in selected areas of the surface of the wells of the multi-well plates. If the area of measurement is centralized, so that only the middle of the well is measured, a difference in nematode autofluorescence (fluorescence which occurs in the absence of any external marker molecule) can be observed in the wells containing nematodes that move normally as compared to wells containing nematodes that are defective for movement. For the wells containing the nematodes that move normally, a low level of autofluorescence will be observed, whilst a high level of autofluorescence can be observed in the wells that contain the nematodes that are defective in movement.

In an adaptation of the movement assay, autofluorescence measurements can be taken in two areas of the surface of the well, one measurement in the centre of the well, and one measurement on the edge of the well. Comparing the two measurements gives analogous results as in the case if only the centre of the well is measured but the additional measurement of the edge of the well results in an extra control and somewhat more distinct results.

The movement assay can be used for the same purposes as the pharynx pumping assay described above i.e. the movement assay can be used to identify chemical substances that alter the movement behaviour of the nematode and hence may have an effect on muscle and/or neuronal activity, for the identification of genetic enhancers, suppressors and modulators of a selected compound having a known effect on nematode worms or for the identification of chemical substances that are enhancers, suppressors or modulators of a

selected compound. Chemical substances which are identified using the movement assay as having an effect on the movement behaviour of nematode worms (summarised in figure 13) are generally found to belong to the class of CNS-related drugs but also include GABA antagonists, NMDA antagonists, m-Glu antagonists and adrenergic antagonists.

As with the other screening methods described herein the movement assay methods are preferably carried out using worms of the genus *Caenorhabditis*, most preferably *C. elegans*. The movement assay can be performed using synchronised worm cultures at different growth stages, using male, hermaphrodite or dauer worms or using mutant, transgenic or humanized worms. One mutant *C. elegans* strain, the *ace-1; ace-2* double mutant, is particularly suitable for use in movement assays. This strain does not show any movement and has a spasm-like phenotype. It can therefore be used to screen for chemical substances which rescue the defective movement phenotype. These chemical substances may have a pharmacological effect on muscle and/or neuronal activity.

In a still further embodiment of the invention the step of detecting a signal indicating a phenotypic, physiological, behavioural or biochemical changes in the nematode worms using non-visual detection means comprises detecting changes in the mating behaviour of nematode worms.

The mating behaviour of nematodes such as *C. elegans* is very complex, involving at least following steps: recognition, backing, tail curling, vulva location and copulation. To perform this behaviour, the male nematode has at least 41 specialized additional muscles, 79 additional neurons, 36 extra neuronal support cells, 23 proctodeal cells, and 16

hypodermal cells associated with mating structures. The function of some of the neurons has been described. Also several mutants have been described that show defects in mating behaviour (*C. elegans* II, 5
ibid; J. Sulton et al., W13G 7(2)22; Loer and Kenyon WBG 12(2).80, 1992; Hadju et al., International worm meeting abstract 15 1, 199 1). Due to the complex nature of the mating behaviour, several conditions and mutants have been described to enhance mating 10
behaviour in *C. elegans*. One of these is the use of hermaphrodites with a decreased movement, such as the unc-52 (e444) mutant which shows paralysed behaviour at adulthood.

Because mating involves the activity of both 15
muscles and neurons, screens based on detecting changes in the mating behaviour of nematode worms (the mating assay) can be used to identify chemical substances which may modulate muscle and/or neuronal activity. The mating assay can be used to isolate 20
chemical substances that modulate mating, or to isolate chemical substances that modulate the activity of a compound that effects mating behaviour, or to isolate genes and pathways that are active in the mating behaviour, or to isolate genes and pathways 25
that modulate the activity of a compound that affects mating behaviour. In other words, the mating assay can be used for all the same purposes as the pharynx pumping assays and movement assays described above.

C. elegans are not able to perform mating in 30
liquid media. The high-throughput screens based on mating behaviour are therefore performed in semi-liquid conditions. A low-melting agarose solution of approximately 0.5% is suitable for this purpose. This semi-liquid medium gives sufficient support for the 35
nematodes to move toward each other and to perform

mating.

Mating performance is measured by measuring the number of eggs or offspring produced from a mating experiment. In a particular embodiment of the invention specific strains are used which are not able to generate offspring by self-fertilization. Such so-called hermaphrodite 'non-selfers' cannot generate offspring, but hermaphrodites that have mated will generate offspring. The offspring can be measured directly by the previous described movement test, or a marker dye can be added to the medium such as calcein-AM so that the previously described pharynx pumping screen can be performed. Alternatively, specific antibodies and fluorescent antibodies can be used to detect the offspring. Any specific antibody that only recognizes eggs, or L1 or L2 or L3 or L4 stage worms, will only recognize offspring, such a specific antibody that recognizes an antigen on the L1 surface has been described by Donkin and Politz, W13G 10(2):71. Finally, the number of eggs or offspring in each well can be counted directly using a FANS device.

In another embodiment of the invention either the male worms or the hermaphrodite worms can be transgenic worms which stably express a marker molecule such as an autonomous fluorescent protein (GFP or BFP) or a luminescent marker in some or all cell types. The offspring generated from mating of these transgenic worms will also express the marker molecule and hence can be easily measured using a multi-well plate reader or a FANS device. In the case that the male worms are the transgenic worms expressing the marker then the hermaphrodites do not need to be 'non-selfers' since only offspring resulting from the mating of males and hermaphrodites will express the marker whilst offspring generated from hermaphrodite self-fertilization will not harbor

the marker molecule. The offspring resulting from mating and self-fertilization can thus be distinguished. In the case that the hermaphrodite worm is the transgenic strain expressing the marker molecule the hermaphrodite strain is preferably also a 'non-selfer' strain.

The mating assay can also be performed using *C. elegans* in which the function of a male-specific neuron involved in mating behaviour is disrupted. The examples included herein provide a list of male-specific neurons involved in mating behaviour. The function of one or more of these neurons can be disrupted for example by expression of one of the toxic genes listed above in connection with the pharynx pumping assays. By using *C. elegans* which have defects in one or more specific neurons it is possible to perform screens to identify chemical substances which act on a specific neuronal signalling pathway. The chemical substances identified using such screens may have CNS-related pharmacological activity.

The mating assay can also be performed using transgenic *C. elegans* which exhibit altered mating behaviour as a result of the expression of a toxic gene in a specific tissue or cell type. Suitable transgenic *C. elegans* can be constructed according standard techniques known in the art using one of the toxic genes listed above under the control of an appropriate tissue- or cell type-specific promoter. Promoters which may be useful for this purpose include the *her-1* P2 promoter which directs gene expression in CP9, the *mab-18* (alternative splice of *pax-6* homologue *vab-3*) promoter which directs gene expression in ray 6 and the *spe-T1* promoter which directs gene expression in 60 cells of the spermatheca.

In a still further embodiment of the invention the step of detecting a signal indicating a phenotypic, physiological, behavioural or biochemical changes in the nematode worms using non-visual detection means
5 comprises detecting changes in the egg laying behaviour of the nematode worms.

The vulva of hermaphrodite *C. elegans* nematodes contains at least 24 cells and several neurons, of which the HSN neurons are considered to be the most
10 important in egg-laying. Furthermore at least 8 uterine muscles have been described. Several mutants have been described in gonad development, egg-laying, vulva development and function (The nematode *Caenorhabditis elegans*, *ibid.*; *C. elegans* II, *ibid.*),

15 Accordingly, high-throughput screening assays can be developed which use a read-out based on detection of changes in the egg laying behaviour of nematodes such as *C. elegans*. Again, assays based on detection of egg laying can be used for the same purposes as the
20 pharynx pumping and movement assays described herein. In these assays the number of eggs layed is detected by counting the numbers of resultant offspring used the techniques described above for the mating assay.

In a still further embodiment of the invention the
25 step of detecting a signal indicating a phenotypic, physiological, behavioural or biochemical change in the nematode worms using non-visual detection means comprises detecting a change in the defecation behaviour of the nematode worms.

30 Defecation in nematodes such as *C. elegans* is achieved by periodically activating a stereotyped sequence of muscle contractions. These contractions are started in the anterior body wall muscles. At the zenith of the anterior body contractions the four anal
35 muscles also contract. The four anal or enteric

muscles are the two intestinal muscles, the anal depressor and the anal sphincter. In addition to this series of muscle contractions, specific neurons are also involved in the regulation of defecation, including the motor neurons, AVL and DVB. Since defecation requires the activity of both muscles and neurons high-throughput screening assays can be developed which use a read-out based on detection of changes in the defecation behaviour of nematodes such as *C. elegans*. Again, assays based on detection of egg laying can be used for the same purposes as the pharynx pumping and movement assays described herein.

The defecation assay is preferably performed using *C. elegans* mutants which have a defective defecation behaviour and particularly with *C. elegans* mutants which are constipated. Several mutants with all kinds of defects in the defecation cycle have been reported (Thomas, Genetics 124: 855-872, 1990; Iwasaki et al., PNAS 92: 10317-10321, 1995; Reiner et al., Genetics 141: 961-976, 1995). However, the defecation assay can also be performed using wild-type worms or worms with no defecation defects which allow screening for compounds which are inhibitors of defecation. As defecation in *C. elegans* requires the activity of muscles and neurons, compounds which alter the rate of defecation may potentially have CNS-related pharmacological activity.

The rate of defecation of nematodes such as *C. elegans* can be easily measured using a marker molecule which is sensitive to pH, for example the fluorescent marker BCECF. This marker molecule can be loaded into the *C. elegans* gut in the form of the precursor BCECF-AM which itself is not fluorescent. If BCECF-AM is added to the medium in the wells of the multi-well plate the worms will take up the compound which is

then cleaved by the esterases present in the *C. elegans* gut to release BCECF. BCECF fluorescence is sensitive to pH and under the relatively low pH conditions in the gut of *C. elegans* (pH<6) the compound exhibits no or very low fluorescence. As a result of the defecation process the BCECF is expelled into the medium which has a higher pH than the *C. elegans* gut and the BCECF is therefore fluorescent. The level of BCECF fluorescence in the medium (measured using a multi-well plate reader on settings Ex/Em=485/550) is therefore an indicator of the rate of defecation of the nematodes.

Defecation can also be measured using a method based on the luminescent features of the chelation of terbium by aspirin. The method requires two pre-loading steps, first the wells of a multi-well plate are pre-loaded with aspirin (prior to the addition of the nematode worms) and second, bacteria or other nematode food source particles are pre-loaded with terbium using standard techniques known in the art. *C. elegans* are then placed in the wells pre-loaded with aspirin and are fed with the bacteria pre-loaded with terbium.

The terbium present in the pre-loaded bacteria added to the wells will result in a low level of background luminescence. When the bacteria are eaten by the nematodes the bacterial contents will be digested but the terbium will be defecated back into the medium. The free terbium will then be chelated by the aspirin which was pre-loaded into the wells resulting in measurable luminescence. The luminescence thus observed is therefore an indicator of nematode defecation.

The invention will be further understood with reference to the following experimental examples

together with the accompanying Figures in which:-

Figure 1 is an overview of the neurons and transmitters that are known to have a direct influence on the pumping rate of the *C. elegans* pharynx.

Figure 2 illustrates the principle of the pharynx pumping assay as demonstrated with calcein-AM.

Figure 3 shows an example of the detection of enhancers of the pumping rate of the *C. elegans* pharynx, using a fluorescent read-out.

Figure 4 shows an example of the detection of inhibitors of the pumping rate of the *C. elegans* pharynx, using a fluorescent read-out.

Figure 5 lists enhancers of the *C. elegans* pharynx pumping rate isolated from the pharmacopoeia.

Figure 6 lists inhibitors of the *C. elegans* pharynx pumping rate isolated from the pharmacopoeia.

Figure 7 shows dose-response curves for the inhibitors tamoxifen, BP554 and pimazide.

Figure 8 shows a dose-response curve for the enhancer clomipramine, showing the toxic effect of DMSO.

Figure 9 shows a dose-response curve for thapsigargin showing the enhancer effect at high concentrations and the inhibitor effect at high concentrations.

Figure 10 illustrates the principle of the movement assay.

Figure 11 illustrates the principles of chemical substrate selection and antagonist selection using the movement screen.

- 5 Figure 12 shows the results of a representative movement assay illustrating the change in nematode autofluorescence (y-axis) with time (x-axis).

10 Figure 13 is a partial list of hits obtained when screening 800 compounds from a pharmacopoeia library using a movement assay with *C. elegans*. The hit compounds are scored as causing a detectable change in the movement behaviour of *C. elegans*.

- 15 Figure 14 summarises results of screening of the Tocris compound library (Bristol, UK) using a pharynx pumping assay with *C. elegans*.

20 Example 1 Distribution of nematodes, and dilution of compounds.

25 The basic protocol for performing a screen using the method of the invention is described for multi-well plates with 96 wells, but other multi-well plates with 6, 12, 24, 3 84 or 1536 wells could be used.

30 Preferentially, synchronized worms are used. The production of large amounts of synchronized worms has been described in (Methods in cell biology, Vol. 48, *ibid*). After the worms have grown to the preferred stage, they are washed in M9 buffer prior to further use, and re-suspended in an assay buffer (40mM NaCl, 6mM KCl, 1mM CaCl₂, 1mM MgCl₂). (10 X M9 buffer: 30g KH₂PO₄, 60 g Na₂HPO₄, 50 g NaCl, 10 ml MgSO₄ 1M, made
35 up to 1 litre with H₂O). Other buffers than M9 buffer

can be suitable for this purpose.

The worms are then diluted and resuspended in semi-soft agar (final concentration of 0.25% low melting agarose in M9 buffer). This procedure results in an equal, homogenous and stabilised suspension of the nematodes. Other polymers than low melting agarose can be used in this procedure. The presence of a homogenous worm suspension facilitates the equal distribution of the worms in the multi-well plates, but is not essential for the described screening assay. Any other method that results in a homogenous distribution of the nematodes worms over the wells will be useful. More specifically, the use of a worm dispenser will result in even a better, and hence a more equal distribution of the worms over the wells of the multi-well plate.

The worms are distributed in the multi-well plates using electronic 8 channel pipettes. In a preferred set-up of this experiment 40 +/- 5 worms are added to every well of the microtiter plate.

The chemical substances are made soluble in DMSO. Any other solvent can be used for this purpose, but most selected chemical substances appear to be soluble in DMSO. The chemical substance is added in the wells at various concentrations. but preferentially a concentration between 3 to 30 μM is chosen as this gives the clearest results. It possible to screen for dosage effects by varying the concentration of the chemical substance from less than 1 μM up to 100 μM . The concentration of the DMSO should not be too high and preferentially should not exceed 1%, more preferentially the concentration of the DMSO should not exceed 0.5% and even more preferentially, the concentration of the DMSO is lower than 0.3%.

Example 2

Conditions for a pharynx pumping assay.

Depending on the specific assay which it is desired to perform, different *C. elegans* strains can be used. Screens to select for chemical substances inhibiting the pumping rate of the *C. elegans* pharynx are generally performed with mutant *C. elegans* strains which have a constitutively pumping pharynx. Wild-type worms can also be used in this screen, but the mutants worms are preferred. Other *C. elegans* mutants can be used in this screen to select for inhibitors of pumping. The selected mutant *C. elegans* with the constitutively pumping pharynx pumps medium into the gut at a constant rate and reduction/rescue of this phenotype can easily be scored, which facilitates the detection and selection of chemical substances.

To select for chemical substances that enhance the pumping of the *C. elegans* pharynx the screen is generally performed using wild-type *C. elegans* worms but other mutants could be used in this screen. A wild type worms will not pump or show a reduced pumping rate in liquid medium that doesn't contain any food source as the food source is one of the signals to induce pharynx pumping. As wild-type worms show a reduced pumping rate in this assay, enhancement of the pumping rate can easily be scored.

The pumping rate of the pharynx is measured indirectly by adding a marker molecule precursor such as calcein-AM to the medium and measuring the formation of marker dye in the *C. elegans* gut. Calcein-AM is cleaved by esterases present in the *C. elegans* gut to release calcein, which is a fluorescent molecule. The pumping rate of the pharynx will determine how much medium will enter the gut of the worm, and hence how much calcein-AM will enter the

gut of the worm. Therefore by measuring the accumulation of calcein in the nematode gut, detectable by fluorescence, it is possible to determine the pumping rate of the pharynx.

5 Chemical substances that alter the pumping rate of the pharynx will result in more or less uptake of the calcein-AM and hence in more or less fluorescent signal. Moreover, using a multi-well plate reader, the fluorescence can be measured rapidly and
10 quantitatively, resulting in a fast, quantitative high throughput screening method for the identification of chemical substances with potential pharmacological activity.

 To perform the pharynx pumping screen with
15 calcein-AM, a concentration of between 1 and 100 μ M calcein-AM is added into the medium. Preferably 5 to 10 μ M calcein-AM is used. Fluorescence was measured is measured using a multi-well plate reader (Victor2, Wallac Oy, Finland) with following settings: Ex/Em =
20 485/530.

 This measurement of the pharynx pumping rate by detecting the accumulation of a marker molecule is not limited to calcein-AM. Other precursors can be used and thus the assay as described here can be changed
25 to be suitable for other precursors. The precursor can be cleaved by esterases, but could also be a substrate for other enzymes in the nematode gut. Furthermore, the marker molecule should not necessary be a fluorescent molecule, but can be a molecule detectable
30 by other methods. Most of these precursor substances are commercially available or could be synthesized according to methods known in the art. Some examples are:

35 With a fluorescent read out:

 -Esterases substrates: Calcein-AM, FDA, BCECF-AM

-Alkaline phosphatase substrates: Fluorescein
diphosphate (FDP)

-Endoproteases; Aminopeptidase substrates: CMB-leu

5

With a luminescent read out:

-alkaline phosphatase substrates: AMPPD

With a colour read out.

10 -Glucuronidase substrates: X-gluc

Other target enzymes present in the gut for which
substrates can be found or developed are DNases,
ATPases, lipases and amylases. An overview of various
15 marker molecules, mainly fluorescent can be found in
"Handbook of fluorescent probes and research
chemicals, molecular probes, ed. by R. P. Haughland"

20 Example 3 Testing the pharynx pumping assay with
compounds from the pharmacopoeia

160 well known drugs selected from the
pharmacopoeia were used in a screen to test the
25 performance of the pharynx pumping. The drugs tested
belong to a variety of categories, which included
analgesics, antidiabetics, antiarrhythmics, calcium
channel blockers, diuretics, cholinesterase
inhibitors, proton pump inhibitors and
30 antidepressants.

The drugs were randomly distributed over the wells
of two 96-well multi-well plates. The pumping rate of
the *C. elegans* pharynx was measured using calcein-AM
as described in Example 2. *C. elegans* wild-type
35 strain N2 was used to select for enhancers of the
pumping phenotype, and a mutant *C. elegans* strain with

a constitutively pumping pharynx was used to detect inhibitors of pumping.

5 In a first assay, the substrate calcein-AM was added to the medium at the same time as the worms and the compounds. The fluorescence was measured after approximately one hour.

10 In a variation of this protocol, compounds and worms are added to the medium first and incubated for approximately 1 hour. After this incubation period that allowed for the chemical substances to activate or to inhibit the pumping rate of the pharynx, calcein-AM was added. The plates were then further incubated for one hour prior to fluorescence measurement in the microtiter plate reader.

15 Although a broad range of chemicals have been selected from the pharmacopoeia with a variety of actions, most if not all of the compounds that had an activity on the pharynx pumping rate belong to the family of CNS drugs, calcium channel inhibitors and muscle relaxants, indicating that the *C. elegans* pharynx assay is a good model system to screen for compounds that have activity in the above described areas.

25 The variation of the protocol resulted in the detection of some new compounds, next to the compounds that have previously been detected; these include the chemicals metrifonate, physostigmine, atropine, L-Hyoscyamine, diphenylhydantoin and ZAPA. All these compounds are known as CNS drugs or are used to treat Alzheimer's disease or are used as antipsychotic, antidepressant or antiepileptic drugs.

Example 4

Selecting for the mode of action of a compound and
selecting compounds which act on specific targets.

5 Amongst 14 types of pharyngeal neurons, at least
the neurons, 11, 12, 13, M3, MC, NSM, M1, RIP and M4
have been shown to be important for pharynx pumping,
The neurons MC, M3, M4 and NSM are known to regulate
the contraction/pumping rate of the pharynx. They
10 control respectively the rate of pumping, timing of
muscle relaxation, isthmus peristalsis and the
perception of food. The main neurotransmitters
involved in neuronal signal transduction in the
nematode *C. elegans* are acetylcholine and serotonin,
15 glutamate, octopamine, dopamine and GABA (The nematode
Caenorhabditis elegans ed. by W. B. Wood et al., CSHL
press 1988, page 337-392).

From the drugs selected in the basic pharynx
screen (Example 3) it is clear that the pharynx
20 pumping rate is influenced by inhibitors and agonists
of neurotransmitters, and by compounds that inhibit or
enhance neurotransmitter pathway calcium channels,
sodium/calcium channels, chloride channels. These
chemical substances are used in a very wide range of
25 prescribed drugs, such as anti-depressants, anti-
psychotics, anxiolytics, tranquillizers,
antiepileptics, muscle relaxants, sedatives, anti-
migraine drugs, analgesics and hypnotics. Some of
these Central Nervous System (CNS) related drugs have
30 applications in disease areas such as CNS related
genetic diseases as Parkinson's disease and
Alzheimer's disease.

To overview the present CNS related drugs, it is
best to classify them according to their biochemical
35 function in the neurotransmitter pathway cascade. In
brief, CNS related drugs can at least have influence

on the following features of the pathway:

- 5 - A CNS drug can have influence on the precursor compounds, or can be precursor molecule for the synthesis of a neurotransmitter.
- A CNS drug can enhance, inhibit or modulate the synthesis of a neurotransmitter
- A CNS drug can have a function in the depletion of the transmitter.
- 10 - A CNS drug can prevent or stimulate the release of the transmitter from the synaptic vesicles in the synaptic cleft.
- A CNS drug can function as a receptor inhibitor or stimulator.
- 15 - A CNS drug can mimic the transmitter.
- A CNS drug can function as conduction inhibitor or activator.
- A CNS drug can function as an activator or inhibitor of the conduction blockade.
- 20 - A CNS drug prevent or stimulate the re-uptake of transmitter after firing of the neuron.
- A CNS drug can functions as a false transmitter (-/+).

25 Next to these features that are all related to the neurotransmitter pathways, a lot of CNS related drugs can be found in the classes of chloride channel blockers, sodium/calcium channel blockers, calcium blockers, and other ion channel blockers.

30 To screen for CNS related drugs, several "in vitro" screening assays have been developed in the prior art. These screening methods, designated as "in vitro binding assays" or "cloned transporter assay systems" are well known to persons skilled in the art.

35 For these assays, cell membranes harboring a specific type of receptor are isolated from mammalian tissue or

specific tissue cultures. In most cases these membranes are isolated from cells that over-express the desired receptor. Depending on the type of receptor that is present in the membrane,

5 neurotransmitters such as acetylcholine, dopamine, serotonin, glutamate, GABA and octopamine, but also hormonal substances such as norepinephrine, adrenaline and others are the subject of the screening assay. When the receptor ligand (being the neurotransmitter

10 in most cases) is radioactive labelled, it is possible to measure the binding rate of the ligand to the receptor. Experimental conditions can then be set-up that compares the binding rate of the radioactive ligand to the receptor. Putative CNS drugs and other

15 chemical substances can then be isolated that alter the binding of the ligand to the receptor. Several variations of this methodology have been developed, some of which are able to isolate compounds that inhibit re-uptake of the ligand such as serotonin,

20 norepinephrine and dopamine (Koppel et al., Chem. Biol. 1995, Jul 2:7 483-7; Beique et al., Eur. J. Pharmacol. 1998, May 15 349:1 129-32)

Other systems that have been developed for the screening of CNS related drugs involve isolated

25 tissues or organs from mammals. Furthermore systems have been described to isolate CNS related drugs, with living animals such as mice.

Although these screening assays can be used to isolate antagonist of neurotransmitters, these "in

30 vivo" assays do not reflect the in vivo effect of the isolated compound, as only the association with the desired receptor is monitored. Moreover for every potential target in the neurotransmitter pathway cascade, an "in vitro binding assay" needs to be

35 developed. Furthermore, for some of the putative targets for CNS related drugs as described above, no

assays have been developed or these assays are difficult to develop, or no high throughput screening is possible. All known assays with tissue and animal models also suffer from the latter problem. Moreover the assays using animal tissues or organs involve the killing of large amounts of animals, and screening methods based on the use of living animals are increasingly to be avoided due to issues of animal welfare.

The pharynx pumping assay methodology can be used to determine in which neurotransmitter pathway a compound shows activity (acetylcholine, dopamine, serotonin, glutamate, octopamine, GABA, etc.). Furthermore it is possible to determine the mode of action of newly isolated chemical substances and screen selectively in a certain pathway for chemical substances with potential pharmacological activity.

A collection of *C. elegans* nematode mutants have been constructed which are defective in one or more genes. The defect can be introduced stably by standard technology (i.e. gene knock-outs) but can also be transiently introduced by RNAi technology. Both techniques are well known in the field of *C. elegans* genetics. The genes that are affected in the nematodes of this collection are genes that are those involved in one or more neurotransmitter pathways. Examples of affected genes are genes that code for neurotransmitter receptors such as muscarinic receptors, glutamate receptors, hormone receptors, 5-HT receptors, cannabinoid receptors, adrenergic receptors, dopaminergic receptors, opioid receptors, GABA receptors, adenosine receptors, VIP receptors, nicotinic receptors, proteins involved in neurotransmitter synthesis or neurotransmitter release pathways and G-protein coupled receptors, genes encoding proteins for G-protein coupled second

messenger pathways such as adenylate cyclase, protein kinase A, cAMP responsive element binding proteins, phospholipase C, genes encoding for functions in gap junctions and genes encoding for ion channels and ion pumps.

These mutants can be used in a pharynx pumping screen as described in the previous Examples. The results of this screening give an indication of the pathway or mode of action of a compound.

In addition to these mutants, transgenic worms have also been constructed. *C. elegans* can be engineered to express human genes using standard technology (described in Methods in Cell Biology, vol. 48). Once again, both transient and stable transgenic nematodes can be constructed, and the methods for engineering the expression of heterologous and homologous transgenes in the nematode *C. elegans* are well known within the field. These transgenes can be expressed solely in cells of the pharynx with the use of pharynx-specific promoters, but could also be expressed solely in the neurons affecting the pumping rate of the pharynx.

To screen for and to isolate chemical substances that are active in the area of CNS related drugs, the transgenes expressed in the transgenic *C. elegans* can encode neurotransmitter receptors such as muscarinic receptors, glutamate receptors, hormone receptors, 5-HT receptors, neurotransmitter synthesis, neurotransmitter release pathways and G-protein coupled receptors. These transgenes can be protein encoding sequences of human origin. At least 400 G-protein coupled receptors have been sequenced so far. Furthermore genes encoding proteins for G-protein coupled second messenger pathways such as adenylate cyclases, protein kinase A, cAMP responsive element binding proteins, phospholipase C and genes encoding

for functions in gap junctions and genes encoding for ion channels and ion pumps could be expressed in the pharynx or in the neurons of the nematode.

The transgenic *C. elegans* described above can have a wild-type genetic background or can be mutant *C. elegans* strains. Preferably the worms are humanized, which means that a transgene which is a protein-encoding nucleic acid sequence of human origin is expressed in a worm made mutant for the *C. elegans* gene encoding the corresponding protein.

An extensive list of mutants which may be suitable for use in pharynx pumping assays can be found in *C. elegans* II, (CSHL press) and in neurobiology of the *C. elegans* genome, C. I. Bargmann, Science 282:2028-2033. A complete list of G-proteins can be found in "the complete family of G-protein genes of *Caenorhabditis elegans*, Jansen G. et al., the Worm Breeders Gazette, Vol. 15 (5), Feb. 1999.

Some examples of *C. elegans* mutants with mutations in genes encoding components of neuronal signalling pathways are listed below. The expression of transgenes encoding the corresponding *C. elegans* and human proteins can be engineered in *C. elegans* wild-type or *C. elegans* mutant strains resulting in transgenic and humanized worms respectively:

Neurotransmitters/pathway	<i>C. elegans</i> mutants
Acetylcholine	eat-18, eat-2, chat-1, unc-17
Acetylcholine esterases	ace-1, ace-2, ace-3
Nicotinic acetylcholine receptors	unc-29, unc-38, lev-1, deg-3, acr-2
Dopamine	cat-2, cat-4, bas-1, cat-1, cat-3, cat-5
Serotonin	bas-1, mod-5, goa-1

Neurotransmitters/pathway	<i>C. elegans</i> mutants
Acetylcholine	eat-18, eat-2, chat-1, unc-17
Acetylcholine esterases	ace-1, ace-2, ace-3
Nicotinic acetylcholine receptors	unc-29,unc-38, lev-1,deg-3, acr-2
Glutamate	avr-15,eat-4,glr-1
GABA	unc-47,unc-25,unc-46,unc-49,exp-1
Na ⁺ /K ⁺ ATPases subunits	eat-6
Calcium channels	eat-12,unc-2,unc-36,unc-13
Others	eat-5,unc-7,unc-18,rab-3,snt-1,ric-4,snb-1,unc-64,unc-50,unc-74

Example 5

Dosage response

To determine the sensitivity of the pharynx pumping assay, dilution series were made for some chemical substances. These include the chemicals clomipramine, tamoxifen, BP554, pimazide and thapsigargin. A concentration range was made from less than 1 μ M up to 100 μ M, and the pumping assay was repeated as described in previous examples. From these results distinct dose-response curves could be drafted.

This experiment shows clearly that the pharynx pumping assay is quantitative and can be used to determine the IC₅₀ and ED₅₀ of chemical substances.

Furthermore from this experiment the toxic effect of the chemical substance can be detected. The dosage response curve of the enhancer clomipramine shows clearly the toxic effect of the solvent DMSO at higher concentrations (Figure 8).

Finally it is possible to detect the effect of a

chemical substance on secondary targets or detect side effects, of a chemical substance at various concentrations. This can be seen in the dosage response curve of thapsigargin, known to be an inhibitor of SERCA, which results in a decrease of the pumping rate of the *C. elegans* pharynx (Figure 9). Nevertheless, at low concentration an enhancement of the pumping can be observed. This is the first observation of this feature of thapsigargin. Although further research is necessary to explain this behaviour, which could be caused by a still unknown secondary target of thapsigargin or another side effect, this experiment shows clearly the sensitivity of the pharynx assay, and the use of the pharynx assay to edit dosage response curves.

Example 6

Detecting the activity of chemical substances with genetic techniques.

Other techniques exist to measure the pumping rate of the *C. elegans* pharynx. As the pharynx is muscle, the contractility of the pharynx is dependent on the internal calcium levels. These calcium levels can be measured using specific calcium-sensitive reporter genes.

It has been reported by Kerr et al. (West coast Worm meeting abstract 77, 1998) that increased electrical activity can be detected indirectly by measuring the calcium levels in the *C. elegans* pharynx. The calcium sensitive reporter proteins described therein are Aequorin and GFP-calmodulin (Miyawaki et al., Nature 388:882-887).

In this study GFP-calmodulin was expressed in the pharynx of *C. elegans* and fluorescence was observed

using two-photon microscopy. It has been shown that inhibitors of pumping such as ivermectin and enhancers of pumping such as serotonin influence the observed fluorescence of the GFP-calmodulin in a predicted way.

5 Analogous transgenic worms expressing GFP-calmodulin can be used to screen for chemical substances that influence the pumping rate of the nematode pharynx using the pharynx pumping assay methodology. Analogous to the pumping assay described
10 for calcein-AM in the previous examples, the transgenic worms are placed in multi-well plates and chemical substances are added. The fluorescence of the GFP-calmodulin is then measured rather than calcein
15 fluorescence using the same multi-well plate reader instrument.

 With the use of appropriate promoter sequences, expression of aequorin or GFP-calmodulin can be engineered in other muscle tissues, or even in neurons in order to monitor the calcium levels in these cells.
20 Such transgenics can be used in a screen as described above.

Example 7

25 Genetic enhancer and suppressor screens.

 Genes and hence biochemical pathways can be found that enhance, suppress or modulate the activity of a given compound. When applying a compound to the nematode *C. elegans*, phenotypic changes can be
30 observed, however, the target of the compound or its mode of action can be known or be unknown. The screening method described below can be used to identify genes which suppress or enhance the activity of a compound which has a defined effect on the
35 phenotype of *C. elegans*.

The compound 2,5-diphenyloxazole is an inhibitor of the pumping rate of the pharynx both in wild-type worms and in constitutive pumping worms. It is used herein as an example of a compound which has a defined effect on *C. elegans*.

C. elegans worms are subjected to random mutagenized using standard techniques such as EMS, TMP-UV or radiation (Methods in Cell Biology, Vol. 48). The F1 generation of these mutagenized worms are placed worm by worm in the wells of multi-well plates and the worms allowed to grow and generate offspring. When the offspring have reached the desired growth stage, 2,5-diphenyloxazole and calcein-AM is added. The plates were further incubated for approximately one hour and fluorescence of the generated calcein was measured using a multi-well plate reader. Wells that had a higher fluorescence read-out were scored. The worms in these wells were used for further analysis, as they harbor a mutation in a gene or a pathway that suppresses the activity of 2,5-diphenyloxazole.

An analogous screen was performed with the compound doxepin, which is an enhancer of pharynx pumping. Mutants were scored that show a reduced pumping phenotype in the presence of the compound doxepin.

Example 8

Screening for antagonists of a compound (thapsigargin)

The compound thapsigargin is known to inhibit the activity of the sarco/endoplasmic reticulum calcium ATPase (SERCA). The SERCA protein pumps calcium into the sarco/endoplasmic reticulum and provides the cell with an internal storage of calcium. The internal storage of calcium is important for muscle activity.

In *C. elegans*, inhibiting SERCA activity by applying thapsigargin to the worm results in a decrease in the pharynx pumping rate. Another feature observed by the action of thapsigargin on the nematode worm *C. elegans* is decreased movement, which is a result of the inhibition of SERCA activity of the body wall muscles.

A pharynx pumping screen has been developed to screen for chemical substances that suppress the activity of thapsigargin on SERCA. *C. elegans* nematodes, both wild-type nematodes and nematodes with a constitutive pumping pharynx are placed in the wells of multi-well plates as previous described. Thapsigargin is added to the worms at an inhibitory concentration and calcein-AM is added at a concentration of 5-10 μ M as previous described. Finally the chemical substances to be selected are added. Control wells are also set up containing thapsigargin alone with no second chemical substance.

Analogous to the pharynx pumping screen, fluorescence is measured using a multi-well plate reader. Wells harboring a chemical substance where the measured fluorescence is higher than in the control wells containing no chemical substance are scored. These wells harbor a chemical substance that is an antagonist of the thapsigargin activity, as the inhibitory activity of thapsigargin is suppressed. Chemical substances thus identified may inhibit directly the activity of thapsigargin, or stimulate the activity of SERCA, or have an enhancer activity on the SERCA pathway, and hence on the calcium biology of the organism.

Chemical substances selected in this screen are considered as potential therapeutics, or as hits for the further development of therapeutics in the disease areas which are the cause of a malfunction of the

calcium biology of the organism. Examples of disease areas for which these therapeutics are useful are cardiac hypertrophy, cardiac failure, arterial hypertension, Type H diabetes and Brody disease.

5 In the example given above, thapsigargin is used as an example of a compound having a defined phenotypic effect on *C. elegans* and any compound that has an inhibitory activity on the pharynx pumping rate can be used in an analogous screen.

10 Screens to select for chemical substances that have an antagonist activity on compounds are known to enhance the pumping rate of the pharynx can also be performed. In such an experiment, a chemical substance is scored if it reduces the pumping rate of the
15 pharynx in the presence of the compound known to be an enhancer of pharynx pumping.

 Analogous experiments can be done with compound inhibiting other calcium pumps and even other ion pumps.

20

Example 9

Screening for chemical substances in transgenic, mutant and humanized animals (SERCA-PLB)

25 The human SERCA-2 protein is known to be negatively regulated by at least one protein, known as phospholamban (PLB). Both are expressed in the heart of vertebrates, and an extensive list of literature exists on the features of this interaction.

30 An increase of the internal storage of calcium is general considered to be important for the strength of muscle contraction, and consequently an improvement or increase of this muscle contraction can be realized by enhancing the SERCA activity. Chemical substances that enhance the SERCA activity or inhibit the SERCA-PLB
35 interaction are considered as potential therapeutics,

or as hits for the further development of therapeutics in the disease areas which are the cause of a malfunction of the calcium biology of the cell or organism. Examples of disease areas where an increase of SERCA activity may be beneficial are cardiac hypertrophy, cardiac failure, arterial hypertension, Type 11 diabetes and Brody disease.

There are several SERCA genes and isoforms which are associated with different types of diseases; SERCA2 and PPLB are associated with cardio-vascular diseases, SERCA1 and sarcolipin are associated with skeletal-muscle diseases, and three SERCA genes have been associated with non-insulin-dependent diabetes mellitus.

In order to perform screens to identify chemical substances which modulate the activity of SERCA pathways SERCA genes and PLB have been expressed in *C. elegans*. The expression of these genes can be regulated under the control of several specific promoters with the following activities:

- a) The *C. elegans* myo-2 promoter which promotes expression in the pharynx
- b) The *C. elegans* SERCA promoter which promotes expression in the *C. elegans* muscles, including the pharynx, the vulva muscles and the body wall muscles.

The following transgenics were constructed:

- a) pig and/or human SERCA under the SERCA and/or myo-2 promoter.
- b) pig and/or human SERCA under the SERCA and/or myo-2 promoter in a *C. elegans* mutated for the *C. elegans* SERCA (Knock-outs

and selected mutants).

- c) pig and/or human PLB under the SERCA and/or the myo-2 promoter.
- d) pig and/or human PLB under the SERCA and/or the myo-2 promoter in a *C. elegans* mutated for the *C. elegans* SERCA (Knock-out and selected mutants).
- e) pig and/or human PLB-GFP fusion under the SERCA and/or the myo-2 promoter.
- f) pig and/or human PLB-GFP fusion under the SERCA and/or the myo-2 promoter in a *C. elegans* mutated for the *C. elegans* SERCA (Knock-outs and selected mutants).
- g) pig and/or human SERCA under the SERCA promoter and pig and/or human PLB under the myo-2 promoter.
- h) pig and/or human SERCA under the SERCA promoter and pig and/or human PLB under the myo-2 promoter in a *C. elegans* mutated for the *C. elegans*, SERCA (Knock-out and selected mutants).
- i) pig and/or human SERCA under the SERCA promoter and pig and/or human PLB-GFP under the myo-2 promoter.
- j) pig and/or human SERCA under the SERCA promoter and pig and/or human PLB-GFP under the myo-2 promoter in a *C. elegans* mutated for the *C. elegans* SERCA (Knock-out and selected mutants).

30

Some of these constructed transgenic and mutant animals show a clear change in pharynx pumping rate as could be measured by the fluorescence of calcein in the gut using the calcein-AM pharynx pumping assay.

35 Some of these strains were considered to be useful for

further screen development. As described in the previous examples, the transgenic and mutant animals were placed in the wells of multi-well plates. Calcein-AM and chemical substances under test were then added. The fluorescence of the calcein formed in the gut was measured in a multi-well plate reader set to measure fluorescence. Chemical substances that altered the properties of the pharynx pumping rate, and hence altered the function and activity of the SERCA pathway were selected for further analysis, and can be considered as potential compounds for therapeutic use, or as hits for the further development of therapeutics.

A analogous experiment can be performed with the SERCA1 gene and its regulator Sarcolipin (SLN), to detect chemical substances that alter their activity and/or regulation.

Example 10

20 Screening for chemical substances in transgenic and/or mutant animals (neurodegeneration)

The anatomy of the pharynx of the nematode consists of several parts, containing several cells and cell types. These include the pharyngeal muscles, the pharyngeal epithelial cells, the pharyngeal glands, and the pharyngeal neurons. At least 14 neurons are involved in the function of the neuron from which the most important are I1, I2, I3, M3, MC, NSM, M1, RIP and M4 (reviewed in "The nematode *C. elegans* ed. by W.B. Wood, 1988, CSHL Press).

Mutations or dysfunctions in any part of the pharynx (the pharyngeal muscles, the pharyngeal epithelial cells, the pharyngeal glands, and the pharyngeal neurons) will result in an altered pumping rate of the pharynx. Several mutations are known in

the literature to give rise to an altered pumping rate, or to have an altered pharynx morphology.

Another way to alter the cells involved in pharynx function, pharynx pumping and pharynx morphology is by applying using transgenic techniques to the nematode. Expression of toxic genes in one of the cells involved in pharynx anatomy and pharyngeal function will result in degeneration, dysfunction or abnormal development of the respectively cells. As a result the pumping rate of the pharynx will be altered, most probably the pumping rate will be decreased.

Examples of toxic genes that could be used to for this purpose are listed above. Transgenic *C. elegans* can be constructed which express these genes in a tissue specific way. For example, the myo-2 promoter will induce expression in the pharynx muscles, the unc-129 promoter will induce expression in the neuronal cells. For every cell type or tissue, a cell type-specific or tissue-specific promoter can be selected so that degeneration of the tissues can be precisely controlled. Promoters can be selected in such a way that the expression of the toxic gene is only induced in one specific cell.

Mutants and transgenics that have an altered pharynx anatomy or pharynx pumping can then be used in a pharynx pumping screen to select for chemical substances that restore or rescue the genetic or morphological defect. If the mutant or transgenic animal has a decreased pumping rate the screen will preferentially identify chemical substances that enhance the pumping rate. If the mutant or transgenic shows an increased pumping rate, the screen will preferentially identify chemical substances that reduce the pumping rate of the pharynx

Examples of mutants which may be used in pharynx screen are:

	Gene	allele	Pharyngeal phenotype	Other phenotype
	dig-1	n1321	Twisted	
5	eat-6	ad467	relaxation defective	ATPase
	eat-13	ad522	relaxation defective	Slow growing
	goa-1	sy192	increased pumping	hyperactive
	mig-4	rh51	Twisted	
	mlc-2		pumping defects	Larval lethal
10	pha-2	ad427	misshapen pharynx	Larval lethal
	pha-3	ad607	misshapen pharynx	Slow growing
	phm-2	ad538	relaxation defective	
	cha-1	p1152	slow pumping	Unc
	clk-1	e-2519	slow pumping	Slow
15	eat-1	ad427	irregular pumping	Long and thin
	eat-2	ad451	slow pumping	hypers. to cholin.agonist
	eat-3		Very Slow pumping	Misformed
	eat-4		pumping defects	
	eat-5		unsynchronized pumping	
20	eat-7		sleeping	
	eat-8		brief pumping	
	eat-9		irregular pumping	slightly starved
	eat-14		relaxation defects	motion defects
	eat-18		slow pumping	starved
25	eat-x		pumping defect	
	osm		slow pumping	chemotaxis defects
	snt-1		pumping defects	Unc
	unc-11		slow pumping	Kinker
	unc-13		irregular pumping	Paralysed
30	unc-17		slow irregular pumping	Small

Gene	allele	Pharyngeal phenotype	Other phenotype
unc-26		slow pumping	little movement
unc-31		constitutive pumping	Slow
unc-36		irregular pumping	Paralysed
unc-57		slow pumping	Small
unc-58		sticky pumping	Shaker
unc-90		sticky pumping	Short
unc - 105		sticky pumping	poor growth
sma-1		pharynx defects	
sma-2		reduced pumping	
sma-3		pharynx defects	
sma-4		pharynx defects	
exp-2	sa26/+	fast shallow pumping	jerky, egl, constipated

Example 12:

Specific example of the assay with dauers, neuro-degeneration and the use of the daf-7 promoter

The ASI neurons of *C. elegans* are chemical-sensory neurons and are essential for food perception and pharynx pumping. It has previously been reported that the disruption of the ASI or ADF or ASG or ASJ neuron results in dauer formation. These experiments that kill one or more of these neurons were performed with laser ablation. (Schackwitz WS et al., Neuron 17:719-728, 1996). Furthermore it was reported that the Daf-7 (a member of the TGF-beta family) is expressed specifically in the ASI neuron.

In an experiment analogous to example 11, the ASI neuron has been killed, disrupted or altered in its properties. More specifically toxic genes have been

expressed in this neuron by inducing their expression under the control of the daf-7 promoter. Disrupting the ASI neuron in such a way results in the formation of dauers.

5 Such strains were used in screens as previously described. In a first example the resulting dauers were used in a pharynx pumping assay. Dauer worms do not have or have only a reduced pharynx pumping. Chemical substances were identified that cause the
10 worms to bypass the dauer phenotype and hence restore the pharynx pumping. As before, the rate of pharynx pumping was measured using calcein-AM.

 In a second example the dauers were submitted to the movement assay. As dauer worms do not move, and
15 hence precipitate in the wells, they can be used in the movement assay to identify chemical substances that cause the worms to bypass the dauer phenotype and hence alter the movement of the worms. The movement behaviour of the worms was detected using
20 autofluorescence over the centre of the wells.

Example 13:

Specific example of the assay, with dauers.

 Daf-2 ts is a nematode mutant, which grows
25 normally at 15°C but generated 100 % dauer formation at 25°C, these mutants can also be used in screens to isolate chemical substances that cause worms to bypass the dauer phenotype.

 To perform such an assay synchronized Ll Daf-2 ts
30 worms are distributed over the wells of microtiter plates. Synchronized eggs could also have been used. The worms were supplied with food and grown further at 25°C, resulting in dauer formation. After
35 approximately 4 days the chemical under test and calcein-AM is added and fluorescence is measured at selected time intervals, varying from 1 hour to 4

days, keeping the temperature at 25°C. Chemical compounds were scored that caused the worms to bypass the dauer phenotype. Due to the presence of the food substrate, it may be difficult to detect fluorescence using a multi-well plate reader. The FANS device may alternatively be used to measure fluorescence in this instance.

An analogous experiment can be performed in which the chemical under test is added to the wells, approximately together with the L1 worms.

In an other variant of this experiment, large quantities of Daf-2 ts dauers were cultivated. The dauers were then dispensed over the wells of multi-well plates and chemical substances were added. The multi-well plates were placed in a multi-well plate reader set up to perform a movement assay (i.e. to measure autofluorescence). Autofluorescence measurements were recorded at several time intervals varying from 1 hour to 4 days, keeping the wells at 25°C.

Example 14

Screening for chemical substances and compound antagonists with the movement assay.

The nematode mutant (ace-1; ace-2) does not show any movement and has a spasm-like phenotype. The worm does not show any sinusoidal shape, but is straight shaped. This is because the mutant is mutated in the acetylcholine esterases, resulting in high concentrations of acetylcholine in the synapses. Neostigmine, a well known acetylcholine esterase inhibitor, was added to wild-type worms distributed over the wells of a multi-well plate and submitted to the movement assay after approximately 2 hours. As Figure 11, panel 1 shows clearly worms exposed to neostigmine showed a clear decrease in movement.

Hexamethonium and mecamylamine are well known acetylcholine receptor antagonists and hence should repress the overload of acetylcholine in the synapses of the ace1; ace2 mutant, resulting in restoration or rescue of the movement. As receptor antagonist, hexamethonium will also result in a decrease of movement, as it prevents proper signalling. In last panel of figure 11, it is clearly shown that hexamethonium represses the movement of wild-type worms, but significant less than neostigmine (100% represents normal movement of wild-type worms).

In an other experiment, wild-type worms were contacted with inhibitory concentrations of neostigmine to prevent movement. After a small incubation period, various concentrations of hexamethonium were added and the wells were submitted to the movement assay (measurement of autofluorescence). As figure 11 shows, increasing concentrations of hexamethonium resulted in more movement as predicted (hexamethonium is an antagonist), but the upper limit seems to be determined by the inhibitory activity of hexamethonium. At very high concentrations of hexamethonium (although lower than the concentrations shown in last panel) a toxic effect is observed, resulting in a decrease in movement. This toxic effect is probably due to the presence of high concentrations of both neostigmine and hexamethonium.

An analogous experiment was performed with the ace-1;ace-2 double mutant. In this experiment, increasing concentrations of hexamethonium were added to the wells in the absence of neostigmine. The results of both experiments were comparable.

This experiment shows clearly the applicability of the movement assay to select for chemical substances and antagonists of selected compounds.

Example 15

Example of a mating assay using hermaphrodite non-selfers.

High throughput analysis of the nematode mating
behaviour could be performed by counting the
offspring of the mating experiment. First, equal
amounts of male worms were distributed over the wells
of multi-well plates. Hermaphrodites were then added
over the wells in such a way that the every well
contains an equal amount of hermaphrodites. The
ratio between males and hermaphrodites can be varied
from experiment to experiment.

The hermaphrodite chosen in this experiment has a
reduced self-offspring or the offspring is non-viable
or preferentially the hermaphrodite is self-sterile,
such as the hermaphrodites mutant in the *fer* or *spe*
genes. Furthermore, to enhance mating the self-
sterile hermaphrodite has preferentially a reduced
movement or no movement phenotype. The males in this
experiments can be wild-type males, or mutant males,
or transgenic males, or humanized males.

Mating behaviour is assessed by measuring the
total number of offspring produced, as described
above.

25

Example 16

Example of a mating assay hermaphrodite non-selfers
expressing GFP

A mating assay has also be performed with a
specific self-sterile transgenic hermaphrodite that
has a reduced movement phenotype and expresses stably
GFP. All offspring of this mating assay express GFP
and hence the number of offspring can easily be
detected by measuring the GFP fluorescence using a
multi-well plate reader or a FANS. Hermaphrodites
expressing other makers such as luminescent markers

can be used in an analogous experiment.

Example 17

Example of a mating assay males expressing GFP

- 5 In another variant of the mating assay the
hermaphrodites were chosen in following combinations:
- a) The hermaphrodites were wild-type
hermaphrodites, or hermaphrodites showing a
reduced movement phenotype
- 10 b) The male nematodes were wild-type, transgenic,
mutant or humanized nematodes, expressing GFP.

15 In this experiment, the offspring of the self-
fertilization of the hermaphrodite, and the
offspring resulting from the genuine mating could be
distinguished by following the fluorescence of the
GFP as only the offspring resulting from a mating
showed GFP expression.

20 Example 18

Male-specific neurons.

The following table lists *C. elegans* male-specific
neurons and their role in mating behaviour.
Disruption of one or more of these neurons, for
25 example by expression of a toxic gene, may result in
C. elegans variants which can be useful in mating
screens.

30

Neuron	Structure	Class	Role
CAn	ventral cord	motor	?
CPn	ventral cord	motor	turning
CEMn	head	sensory	?
DXn		motor	?
DVE		inter	?sperm activation or transfer

	Neuron	Structure	Class	Role
	DVF		inter	?sperm activation or transfer
	EFn			turning
	HOA	hook	sensory	vulva location
	HOB	hook	sensory	vulva location
5	PCA	p.c.s.	sensory	vulva location
	PCB	p.c.s.	sensory	vulva location
	PCC	p.c.s.	sensory	vulva location
	PGA	p.a.g.	inter	?
	PGA	p.a.g.	inter	?
10	PVV	p.a.g.	inter	?
	PVY	p.a.g.	inter	backing
	R1A	ray	sensory	dorsal response?
	R1B	ray	sensory	dorsal response?
	R2A	ray	sensory	ventral response?
15	R2B	ray	sensory	ventral response?
	R3A	ray	sensory	?
	R3B	ray	sensory	?
	R4A	ray	sensory	ventral response?
	R4B	ray	sensory	ventral response?
20	R5A	ray	sensory	dorsal response? turning?
	R5B	ray	sensory	dorsal response?
	R6A	ray	sensory	?
	R6B	ray	sensory	?
	R7A	ray	sensory	dorsal response?
25	R7B	ray	sensory	dorsal response? turning?
	R8A	ray	sensory	ventral response? turning?
	R8B	ray	sensory	ventral response? turning?
	R9A	ray	sensory	turning?
	R9B	ray	sensory	turning?

Neuron	Structure	Class	Role
SPC	spicule	motor/proprio	spicule insertion
SPD	spicule	sensory	spicule insertion
SPV	spicule	sensory	inhibits ejaculation

5 Example 19

Further mutant and transgenic *C. elegans*.

The following table lists *C. elegans* mutants which show abnormalities in male mating behaviour which may be used in the mating assays:

10

Gene (Mutant)	Defect
cat-1, cat-2, cat-4, cod-5	Turning
che-2, che-3, che-4, cod-10	Response to contact
cod-1, cod-2, cod-4, cod-6, cod-7, cod-8	Spicule insertion
cod-12, cod-13, cod-14, cod-15	Vulva location
15 ram-1, ram-2, ram-3, ram-4, ram-5	Ray morphology

The following table lists mutant *C. elegans* which may be used in the egg laying assays:

20

Gene (Mutant)	Defect
egl-1, egl-43	HSN function migration and differentiation
egl-1, sem-1, sem-4	vulva muscle development
egl-15, egl-17	sex myoblast migration
egl-10, egl-30	synaptic transmission

25 The egg laying assay can also be performed using transgenic *C. elegans* which exhibit altered egg laying behaviour as a result of the expression of a toxic gene in a specific tissue or cell type. Suitable transgenic *C. elegans* can be constructed according standard techniques known in the art using one of the toxic genes listed above under the control of an appropriate tissue- or cell type-specific promoter. Promoters which may be useful for this

30

purpose include the *lin-31*, *egl-17*, *unc-17* and *unc-53* promoters.

5 The following table lists mutant *C. elegans* which may be used in the defecation assays:

Gene (Mutant)	Defect
aex-1; aex-2, aex-3, aex-4; aex-5, aex-6	aBoc and expulsion
unc-25; unc-47; exp-1; exp-2	constipated (expulsion)
10 pho-1 to pho-7, egl-8	aBoc specific
dec-1, dec-2, dec-4, dec-7, dec-11, dec-12	defecation cycle

15 The defecation assays can also be performed using transgenic *C. elegans* which exhibit altered defecation behaviour as a result of the expression of a toxic gene in a specific tissue or cell type. Suitable transgenic *C. elegans* can be constructed according standard techniques known in the art using one of the toxic genes listed above under the control of an appropriate tissue- or cell type-specific promoter. Promoters which may be useful for this purpose include the *unc-43* and *unc-25* promoters.

25 The following table lists mutant *C. elegans* which may be used in the movement assays:

Gene (Mutant)	Defect
unc-17	acetylcholine receptor; coiler
ace-1; ace-2	acetylcholine esterase; loopy head movement
30 unc-25; unc-47	GABA; shrinker
unc-15; unc-54	paramyosin, myosin; paralysed
unc-36	Ca channel; paralysed

Claims:

1. A method of identifying chemical substances which have potential pharmacological activity using
5 nematode worms, which method comprises the steps of:

(a) dispensing substantially equal numbers of nematode worms into each of the wells of a multi-well assay plate;

10 (b) contacting the nematode worms with a chemical substance;

(c) detecting a signal indicating phenotypic, physiological, behavioural or biochemical changes in the nematode worms using non-visual detection means.

15 2. A method of determining the mode of action of a chemical substance using nematode worms, which method comprises the steps of:

20 (a) dispensing substantially equal numbers of a panel of different mutant nematode worms into each of the wells of a multi-well assay plate;

(b) contacting the nematode worms with the chemical substance; and

25 (c) detecting a signal indicating phenotypic, physiological, behavioural or biochemical changes in the nematode worms using non-visual detection means.

30 3. A method of identifying further components of the biochemical pathway on which a compound having a defined effect on a nematode worm acts, which method comprises the steps of:

(a) subjecting a population of nematode worms to random mutagenesis;

(b) dispensing one mutagenized F1 nematode worm into each of the wells of a multi-well assay plate;

35 (c) allowing the F1 nematode worms to generate F2

offspring;

(d) contacting the nematode worms with the compound; and

5 (e) detecting a signal indicating phenotypic, physiological, behavioural or biochemical changes in the nematode worms using non-visual detection means.

4. A method as claimed in claim 3 which further comprises steps of isolating a gene which is mutated
10 in nematode worms which generate a signal in part (e) using genetic techniques.

5. A method of identifying chemical substances which modulate the effect of a first compound, which
15 compound has a defined effect on nematode worms, which method comprises the steps of:

(a) dispensing substantially equal numbers nematode worms into each of the wells of a multi-well assay plate;

20 (b) contacting the nematode worms with the first compound;

(c) contacting the nematode worms with a further chemical substance; and

25 (d) detecting a signal indicating phenotypic, physiological, behavioural or biochemical changes in the nematode worms using non-visual detection means.

6. A method as claimed in claim 5 wherein the second chemical substance suppresses the defined
30 effect of the first compound on the nematode worms.

7. A method as claimed in claim 5 wherein the second chemical substance enhances the defined effect of the first compound on the nematode worms.

8. A method as claimed in any one of claims 1 to 7 wherein the nematode worms are worms of the genus *Caenorhabditis*.

5 9. A method as claimed in claim 8 wherein the nematode worms are *C. elegans* or *C. briggsae*.

10 10. A method as claimed in any one of the preceding claims wherein the step of detecting a signal comprises detecting a change in a measurable property a marker molecule, whereby a change in the property of the marker molecule indicates a phenotypic, physiological, behavioural or biochemical change in the nematode worms.

15 11. A method as claimed in claim 10 wherein the marker molecule is a fluorescent molecule, a luminescent molecule or a coloured molecule.

20 12. A method as claimed in claim 10 wherein the marker molecule is a precursor of a fluorescent molecule, a precursor of a luminescent molecule or a precursor of a coloured molecule.

25 13. A method as claimed in claim 12 wherein said marker molecule is capable of being cleaved by the action of an enzyme present in the gut of *C. elegans* to generate a fluorescent molecule, a luminescent molecule or a coloured molecule.

30 14. A method as claimed in claim 10 wherein the marker molecule is a genetically encoded marker molecule.

35 15. A method as claimed in claim 14 wherein the

C. elegans are transgenic *C. elegans* which express the genetically encoded marker molecule.

16. A method as claimed in claim 14 or claim 15
5 wherein the genetically encoded marker molecule is an autonomous fluorescent protein, alkaline phosphatase, luciferase, β -glucuronidase, β -lactamase, β -galactosidase or aequorin.

10 17. A method as claimed in any one of claims 1 to 16 wherein the non-visual detection means is a multi-well plate reader.

15 18. A method as claimed in claim 17 wherein the multi-well plate reader performs luminescence, fluorescence or spectrophotometric detection.

20 19. A method as claimed in any one of claims 1 to 16 wherein the non-visual detection means is a FANS device.

25 20. A method as claimed in claim 19 wherein the FANS device performs luminescence, fluorescence or spectrophotometric detection.

30 21. A method as claimed in any one of claims 1 to 9 wherein the step of detecting a signal comprises detecting the size and/or developmental stage of the nematode worms using a FANS device.

22. A method as claimed in claim 21 which comprises detecting eggs, L1 stage, L2 stage, L3 stage, L4 stage, adult worms or dauer worms.

35 23. A method as claimed in any one of the

preceding claims wherein step (a) comprises dispensing substantially equal volumes of a homogeneous suspension of nematode worms into each of the wells of the multi-well assay plate.

5

24. A method as claimed in claim 23 wherein the homogeneous suspension comprises a suspension of *C. elegans* in a viscous solution.

10

25. A method as claimed in claim 24 wherein the viscous solution comprises a solution of a polymer material.

15

26. A method as claimed in claim 25 wherein the polymer material is low melting point agarose.

20

27. A method as claimed in any one of the preceding claims wherein the nematode worms are synchronized in the same growth stage.

25

28. A method as claimed in claim 27 wherein the nematode worms are eggs, L1 stage, L2 stage, L3 stage, L4 stage, adult worms or dauer worms.

29. A method as claimed in claim 27 or claim 28 wherein the worms are hermaphrodites or males.

30

30. A method as claimed in any one of the preceding claims wherein the nematode worms are a wild type strain, a mutant strain, a transgenic strain or a humanized strain.

35

31. A method as claimed in claim 30 wherein said nematode worms are a humanized strain expressing one or more protein-encoding nucleic acid sequences of human origin.

32. A method as claimed in claim 30 wherein said nematode worms are transgenic *C. elegans* expressing a transgene comprising a toxic gene.

5 33. A method as claimed in claim 32 wherein said toxic gene encodes ataxin, alpha-synuclein, ubiquitin, the tau gene product, the Huntington's gene product, the best macular dystrophy gene product, the age-related macular dystrophy product or
10 the unc-53 gene product.

34. A method as claimed in claimed in claim 32 or claim 33 wherein expression of the toxic gene is driven by a tissue-specific promoter which is capable
15 of directing gene expression in a single tissue, a sub-set of cell types, a single cell type or a single cell of *C. elegans*.

35. A method as claimed in claim 34 wherein
20 expression of the toxic gene is driven by the daf-7 promoter.

36. A method of identifying chemical substances which have potential pharmacological activity using
25 nematode worms, which method comprises the steps of:

- (a) dispensing substantially equal numbers of nematode worms into each of the wells of a multi-well assay plate;
- (b) contacting the nematode worms with a sample
30 of a chemical substance;
- (c) detecting changes in the pharynx pumping rate of the nematode worms using non-visual detection means.

35 37. A method of determining the mode of action of

a chemical substance using nematode worms, which method comprises the steps of:

- 5 (a) dispensing substantially equal numbers of a panel of different mutant, transgenic or humanized nematode worms into each of the wells of a multi-well assay plate;
- (b) contacting the nematode worms with the chemical substance; and
- 10 (c) detecting changes in the pharynx pumping rate of the nematode worms using non-visual detection means.

38. A method of identifying further components of the biochemical pathway on which a compound having a defined effect on nematode worms acts, which method
15 comprises the steps of:

- (a) subjecting a population of nematode worms to random mutagenesis;
- 20 (b) dispensing one mutagenized F1 nematode worm into each of the wells of a multi-well assay plate;
- (c) allowing the F1 nematode worm to generate F2 offspring;
- (d) contacting the nematode worms with the compound; and
- 25 (e) detecting changes in the pharynx pumping rate of the nematode worms using non-visual detection means.

39. A method as claimed in claim 38 which further
30 comprises steps of isolating a gene which is mutated in nematode worms which exhibit changes in the pharynx pumping rate in part (e) using genetic techniques.

35 40. A method of identifying chemical substances

which modulate the effect of a first compound, which compound has a defined effect on nematode worms, which method comprises the steps of:

5 (a) dispensing substantially equal numbers of nematode worms into each of the wells of a multi-well assay plate;

(b) contacting the nematode worms with the first compound;

10 (c) contacting the nematode worms with a further chemical substance; and

(d) detecting changes in the pharynx pumping rate of the nematode worms using non-visual detection means.

15 41. A method as claimed in claim 40 wherein the second chemical substance suppresses the defined effect of the first compound on the nematode worms.

20 42. A method as claimed in claim 40 wherein the second chemical substance enhances the defined effect of the first compound on the nematode worms.

25 43. A method as claimed in any one of claims 36 to 42 wherein the nematode worms are worms of the genus *Caenorhabditis*.

44. A method as claimed in claim 43 wherein the nematode worms are *C. elegans* or *C. briggsae*.

30 45. A method as claimed in any one of claims 36 to 44 wherein the step of detecting changes in the pharynx pumping rate comprises contacting the nematode worms with a marker molecule which generates a signal when taken up by nematode worms and
35 detecting the said signal using non-visual detection

detecting the said signal using non-visual detection means.

5 46. A method as claimed in claim 45 wherein the marker molecule is a fluorescent molecule, a luminescent molecule, a coloured molecule, a precursor of a fluorescent marker molecule, a precursor of a luminescent marker molecule or a precursor of a coloured marker molecule.

10

 47. A method as claimed in claim 46 wherein said marker molecule is capable of being cleaved by the action of an enzyme present in the gut of the nematode worms to generate a fluorescent molecule, a luminescent molecule or a coloured molecule.

15

 48. A method as claimed in claim 47 wherein the marker molecule is calcein-AM, BCECF-AM, fluorescein diphosphate (FDP), fluorescein diacetate (FDA), CMB-leu, AMPPD or X-gluc.

20

 49. A method as claimed in any one of claims 36 to 48 wherein the non-visual detection means is a multi-well plate reader.

25

 50. A method as claimed in claim 49 wherein the multi-well plate reader performs luminescence, fluorescence or spectrophotometric detection.

30 51. A method as claimed in any one of claims 36 to 48 wherein the non-visual detection means is a FANS device.

 52. A method as claimed in claim 51 wherein the FANS device performs luminescence, fluorescence or

35

spectrophotometric detection.

53. A method as claimed in any one of claims 36
to 52 wherein said nematode worms are wild-type
5 mutant, transgenic or humanized *C. elegans*.

54. A method as claimed in claim 53 wherein said
C. elegans exhibit an altered pharynx pumping rate.

10 55. A method as claimed in claim 53 wherein said
mutant *C. elegans* carry a mutation in a gene encoding
SERCA protein and/or a PLB protein and/or an SLN
protein.

15 56. A method as claimed in claim 54 wherein said
transgenic *C. elegans* express a transgene encoding a
SERCA protein or a PLB protein.

20 57. A method as claimed in claim 56 wherein
expression of said transgene is driven by a tissue-
specific promoter.

25 58. A method as claimed in claim 56 or claim 57
wherein the transgenic *C. elegans* further carry a
mutation in the *C. elegans* gene encoding SERCA
protein.

30 59. A method as claimed in claim 53 wherein said
C. elegans exhibit altered levels of one or more of
the following neurotransmitters: acetylcholine,
serotonin, glutamate, octopamine, GABA or dopamine.

35 60. A method as claimed in claim 53 wherein said
transgenic *C. elegans* expresses a transgene
comprising a toxic gene.

toxic gene encodes ataxin, alpha-synuclein,
ubiquitin, the tau gene product, the Huntington's
gene product, the best macular dystrophy gene
product, the age-related macular dystrophy product or
5 the unc-53 gene product.

62. A method as claimed in claim 60 or
claim 61 wherein expression of the toxic gene is
driven by a tissue-specific promoter which is capable
10 of directing gene expression in the *C. elegans*
pharynx, in a sub-set of cells of the *C. elegans*
pharynx, in the pharyngeal neurons or in a single
pharyngeal neuron.

15 63. A method as claimed in claim 62 wherein
expression of the toxic gene is driven by the myo-2
promoter, the unc-129 promoter, the tmy-1 promoter or
the daf-7 promoter.

20 64. A method as claimed in claim 60 or claim 61
wherein expression of the transgene is driven by the
daf-7 promoter.

25 65. A method as claimed in any one of claims 36
to 64 wherein the nematode worms are synchronized in
the same growth stage.

30 66. A method as claimed in claim 65 wherein the
nematode worms are eggs, L1 stage, L2 stage, L3
stage, L4 stage, adult worms or dauer worms.

67. A method as claimed in claim 65 or claim 66
wherein the worms are hermaphrodites or males.

35 68. A method of identifying chemical substances

which have potential pharmacological activity using nematode worms, which method comprises the steps of:

- 5 (a) dispensing substantially equal numbers of nematode worms into each of the wells of a multi-well assay plate;
- (b) contacting the nematode worms with a sample of a chemical substance;
- 10 (c) detecting changes in the intracellular levels of ions, metabolites or secondary messengers in cells of the nematode worms using non-visual detection means.

69. A method as claimed in claim 68 which comprises detecting changes in the intracellular
15 levels of calcium, cAMP, diacylglycerol or IP3.

70. A method as claimed in claim 68 wherein the nematode worms are transgenic *C. elegans* expressing a
20 genetically encoded marker molecule, which marker molecule generates a signal in response to changes in intracellular levels of ions, metabolites or secondary messengers and step (c) comprises detecting changes in the signal generated by the genetically
25 encoded marker molecule.

71. A method as claimed in claim 70 wherein the genetically encoded marker molecule is GFP-calmodulin or aequorin.

30 72. A method as claimed in claim 70 or claim 71 wherein the genetically encoded marker molecule is expressed in cells of the pharynx, vulva muscles, body wall muscles or neurons of the transgenic *C. elegans*.

35

73. A method as claimed in any one of claims 68 to 72 wherein the non-visual detection means is a multi-well plate reader.

5 74. A method as claimed in claim 73 wherein the multi-well plate reader performs fluorescent, luminescent or spectrophotometric detection.

10 75. A method as claimed in any one of claims 68 to 72 wherein the non-visual detection means is a FANS device.

15 76. A method as claimed in claim 75 wherein the FANS device performs fluorescent, luminescent or spectrophotometric detection.

20 77. A method as claimed in any one of claims 68 to 76 wherein the nematodes are synchronised in the same growth stage.

78. A method as claimed in claim 77 wherein the nematodes are eggs. L1 stage, L2 stage, L3 stage, L4 stage, adult worms or dauer worms.

25 79. A method as claimed in claim 77 or claim 78 wherein the nematodes are hermaphrodites or males.

30 80. A method of identifying chemical substances which have potential pharmacological activity using nematode worms, which method comprises the steps of:

- (a) dispensing substantially equal numbers of nematode worms into each of the wells of a multi-well assay plate;
 - (b) contacting the nematode worms with a sample of a chemical substance;
- 35

(c) detecting changes in the movement behaviour of the nematode worms using non-visual detection means.

5 81. A method of determining the mode of action of a chemical substance using nematode worms, which method comprises the steps of:

 (a) dispensing substantially equal numbers of a panel of different mutant, transgenic or humanized
10 nematode worms into each of the wells of a multi-well assay plate;

 (b) contacting the nematode worms with the chemical substance; and

 (c) detecting changes in the movement behaviour
15 of the nematode worms using non-visual detection means.

 82. A method of identifying further components of the biochemical pathway on which a compound having a
20 defined effect on nematode worms acts, which method comprises the steps of:

 (a) subjecting a population of nematode worms to random mutagenesis;

 (b) dispensing one mutagenized F1 nematode worm
25 into each of the wells of a multi-well assay plate;

 (c) allowing the F1 nematode worms to generate F2 offspring;

 (d) contacting the nematode worms with the compound; and

 (e) detecting changes in the movement behaviour
30 of the nematode worms using non-visual detection means.

 83. A method as claimed in claim 82 which further
35 comprises steps of isolating a gene which is mutated

in nematode worms which exhibit a change in movement behaviour in part (e) using genetic techniques.

5 84. A method of identifying chemical substances which modulate the effect of a first compound, which compound has a defined effect on nematode worms, which method comprises the steps of:

10 (a) dispensing substantially equal numbers of nematode worms into each of the wells of a multi-well assay plate;

 (b) contacting the nematode worms with the first compound;

 (c) contacting the nematode worms with a further chemical substance; and

15 (d) detecting changes in the movement behaviour of the nematode worms using non-visual detection means.

20 85. A method as claimed in claim 84 wherein the second chemical substance suppresses the defined effect of the first compound on the nematode worms.

25 86. A method as claimed in claim 85 wherein the second chemical substance enhances the defined effect of the first compound on the nematode worms.

30 87. A method as claimed in any one of claims 80 to 86 wherein the nematode worms are worms of the genus *Caenorhabditis*.

 88. A method as claimed in claim 86 or claim 87 wherein the nematode worms are *C. elegans* or *C. briggsae*.

35 89. A method as claimed in any one of claims 80

to 88 wherein the step of detecting changes in the movement behaviour of the nematode worms comprises measuring the level of autofluorescence a sub-region of the material in the wells of the multi-well assay plate.

90. A method as claimed in any one of claims 80 to 89 wherein the non-visual detection means is a multi-well plate reader.

91. A method as claimed in claim 90 wherein the multi-well plate reader performs luminescence, fluorescence or spectrophotometric detection.

92. A method as claimed in any one of claims 80 to 89 wherein the non-visual detection means is a FANS device.

93. A method as claimed in claim 92 wherein the FANS device performs luminescence, fluorescence or spectrophotometric detection.

94. A method as claimed in any one of claims 80 to 89 wherein the nematode worms are synchronized in the same growth stage.

95. A method as claimed in claim 94 wherein the nematode worms are eggs, L1 stage, L2 stage, L3 stage, L4 stage, adult worms or dauer worms.

96. A method as claimed in claim 94 or claim 95 wherein the worms are hermaphrodites or males.

97. A method as claimed in any one of claims 80 to 96 wherein the nematode worms are a wild type

strain, a mutant strain, a transgenic strain or a humanized strain.

5 98. A method as claimed in claim 97 wherein said nematode worms are a humanized strain expressing one or more protein-encoding nucleic acid sequences of human origin.

10 99. A method as claimed in claim 98 wherein said nematode worms are transgenic *C. elegans* expressing a transgene comprising a toxic gene.

15 100. A method as claimed in claim 99 wherein said toxic gene encodes ataxin, alpha-synuclein, ubiquitin, the tau gene product, the Huntington's gene product, the best macular dystrophy gene product, the age-related macular dystrophy product or the unc-53 gene product.

20 101. A method as claimed in claimed in claim 99 or claim 100 wherein expression of the toxic gene is driven by a tissue-specific promoter which is capable of directing gene expression in a single tissue, a sub-set of cell types, a single cell type or a single cell of *C. elegans*.

25 102. A method as claimed in claim 101 wherein expression of the toxic gene is driven by the daf-7 promoter.

30 103. A method of identifying chemical substances which have potential pharmacological activity using nematode worms, which method comprises the steps of:

35 (a) dispensing substantially equal numbers of hermaphrodite nematode worms into each of the wells

of a multi-well assay plate;

(b) dispensing substantially equal numbers of male nematode worms into each of the wells of the said multi-well assay plate;

5 (c) contacting the nematode worms with a sample of a chemical substance; and

(d) detecting the amount of eggs or offspring produced using non-visual detection means.

10 104. A method as claimed in claim 103 wherein the nematode worms are worms of the genus *Caenorhabditis*.

105. A method as claimed in claim 104 wherein the nematode worms are *C. elegans* or *C. briggsae*.

15

106. A method as claimed in claim 105 wherein the hermaphrodite nematode worms and/or the male nematode worms are mutant, transgenic or humanized *C. elegans*.

20 107. A method as claimed in claim 106 wherein the transgenic *C. elegans* express a transgene comprising a toxic gene.

25 108. A method as claimed in claim 107 wherein said toxic gene encodes encodes ataxin, alpha-synuclein, ubiquitin, the tau gene product, the Huntington's gene product, the best macular dystrophy gene product, the age-related macular dystrophy product or the unc-53 gene product.

30

109. A method as claimed in claim 107 or claim 108 wherein expression of the toxic gene is driven by the her-1 P2 promoter, the mab-18 promoter or the spe-T1 promoter.

35

110. A method of identifying chemical substances which have potential pharmacological activity using nematode worms, which method comprises the steps of:

5 (a) dispensing substantially equal numbers of hermaphrodite nematode worms into each of the wells of a multi-well assay plate;

(b) contacting the nematode worms with a sample of the chemical substance; and

10 (c) detecting the amount of eggs or offspring produced using non-visual detection means.

111. A method as claimed in claim 110 wherein the hermaphrodite nematode worms are mutant, transgenic or humanized *C. elegans*.

15

112. A method as claimed in claim 111 wherein the transgenic *C. elegans* express a transgene comprising a toxic gene.

20 113. A method as claimed in claim 112 wherein said toxic gene encodes encodes ataxin, alpha-synuclein, ubiquitin, the tau gene product, the Huntington's gene product, the best macular dystrophy gene product, the age-related macular dystrophy product or
25 the unc-53 gene product.

114. A method as claimed in claim 112 or claim 113 wherein expression of the toxic gene is driven by the lin-31 promoter, the egl-17 promoter, the unc-17
30 promoter or the unc-53 promoter.

115. A method as claimed in claim 106 or claim 111 wherein the transgenic *C. elegans* express a marker molecule.

35

116. A method as claimed in claim 115 wherein the marker molecule is an autonomous fluorescent protein.

117. A method as claimed in any one of claims 103
5 to 116 wherein the step of detecting the amount of eggs or offspring produced comprises adding a specific antibody which binds to eggs, L1 stage, L2 stage, L3 stage or L4 stage nematodes and detecting
10 complexes formed by binding of the antibody to eggs, L1 stage, L2 stage, L3 stage or L4 stage nematodes using non-visual detection means.

118. A method as claimed in any one of claims 103
15 to 116 wherein the non-visual detection means is a multi-well plate reader.

119. A method as claimed in any one of claims 103
20 to 116 wherein the step of detecting the amount of eggs or offspring comprises directly counting the numbers of eggs or offspring using a FANS device.

120. A method of identifying chemical substances which have potential pharmacological activity using nematode worms, which method comprises the steps of:

- 25 (a) dispensing substantially equal numbers of hermaphrodite nematode worms into each of the wells of a multi-well assay plate;
(b) contacting the nematode worms with a sample of the chemical substance; and
30 (c) detecting changes in the defecation behaviour of the nematode worms using a non-visual detection means.

121. A method as claimed in claim 120 wherein the
35 nematode worms are worms of the genus *Caenorhabditis*.

122. A method as claimed in claim 121 wherein the nematode worms are *C. elegans* or *C. brigssae*.

5 123. A method as claimed in claim 122 wherein the nematode worms are mutant, transgenic or humanized *C. elegans*.

10 124. A method as claimed in claim 123 wherein the said mutant *C. elegans* exhibit abnormal defecation behaviour.

125. A method as claimed in claim 124 wherein the mutant *C. elegans* are constipated.

15 126. A method as claimed in claim 123 wherein said transgenic *C. elegans* express a transgene comprising a toxic gene.

20 127. A method as claimed in claim 126 wherein said toxic gene encodes encodes ataxin, alpha-synuclein, ubiquitin, the tau gene product, the Huntington's gene product, the best macular dystrophy gene product, the age-related macular dystrophy product or the unc-53 gene product.


25

128. A method as claimed in claim 126 or claim 127 wherein expression of the toxic gene is driven by the unc-43 promoter or the unc-25 promoter.

30

FIG. 1.


Pharynx multiplex screen: X muscles; X neurones




1/14

THIS PAGE BLANK (USPTO)

FIG. 2. Assay Principle




Upon Pharynx pumping, Calcein-AM passes in the gut, gets cleaved by gut esterases. Thus fluorescence accumulates in the gut according to Pharynx pumping rate/drinking




THIS PAGE BLANK (USPTO)

FIG. 3. Enhancers are detected with
C. elegans N2 strain (Wild type)



THIS PAGE BLANK (USPTO)

FIG. 4. Inhibitors are detected using
Constitutive Pumping Mutants



THIS PAGE BLANK (USPTO)

FIG. 5. Enhancers found as positives

Compound name	Mode of action	Disease area	Positives after 1 hour incubation
Clomipramine	ser uptake inhibitor	Antidepressant	
Amiripryline	ser uptake inhibitor	Antidepressant	
Desipramine	ser uptake inhibitor	Antidepressant	
Fluvoxamine	ser uptake inhibitor	Antidepressant	
Nortriptyline	ser uptake inhibitor	Antidepressant	
Imipramine	ser uptake inhibitor	Antidepressant	
Fluoxetine	ser uptake inhibitor	Antidepressant	+
Doxepin	unknown	Antidepressant, Antipruritic	+
nordoxepin	unknown	Antidepressant, Antipruritic	+
mianserin	5HT antagonist		+
Norclomipramine	ser uptake inhibitor	Antidepressant	
Cyproheptadine	Ser receptor antagonist	Antihistaminic, antipruritic, appetite stim.	
Cyclobenzaprine	*	Psychomotor depressant, muscle relaxant	

5/14

THIS PAGE BLANK (USPTO)

FIG. 6. Inhibitors found as positives


Compound name	Mode of action	Disease area	Positives after 1 hour incubation
Pimozide	D2 antagonist	Antipsychotic	
Haloperidol	D2 antagonist	Alzheimer, Antipsychotic	
Trazadone	serotonine uptake blocker metaboite D2 antagonist	Alzheimer, Antidepressant, Antipsychotic	
BP554	5HT1-agonist		
Ivermectin	chloride channel blocker	Antihelminthic	
Levamisole		Antihelminthic	
Metrifonate	Cholinesterase inhibitor	Antihelminthic, Alzheimer	+
Physostigmine	Cholinesterase inhibitor	Alzheimer	+
Tamoxifen	Chloride Channel blocker	antihistamine	
Flunarizine	Na/Ca Channel blocker	Antipsychotic	
Thapsigargin	"Calcium Channel blocker"		
alpha NETA	Inhibitor of Choline acetyltransferase		
Atropine	Cholinergic antagonist		+
L-Hyoscyamine	Cholinergic antagonist	Active form of Atropine	+
Diphenylhydantoin		anticonvulsant, antiepileptic	+
ZAPA	GABA-antagonist		+
2,5-diphenyloxazole			

7/1/9


THIS PAGE BLANK (USPTO)

FIG. 7. Dose Response curves of inhibitors


Effect of Tamoxifen



Effect of BP554



Effect of Pimazide on Pumping in H28




THIS PAGE BLANK (USPTO)

4/16/8

Enhancer dose response curve

Effect of Clomipramine




8/14

THIS PAGE BLANK (USPTO)

FIG. 9

Dose response curve of Thapsigargin

effect of thapsigargin on drinking in N2
and HD8




9/14

THIS PAGE BLANK (USPTO)

FIG. 10.


Movement

Worms in solution



No-movement

Precipitated worms




Signal detection:

Low Optical Density

High Optical Density


Movement

Worms in solution



No-movement

Precipitated worms



Low Optical Density

High Optical Density

Versus

Versus

Low Optical Density

Low Optical Density

10/11/12

THIS PAGE BLANK (USPTO)

WT + neo a + increased C. of keratin
←





FIG. 11

11/11

THIS PAGE BLANK (USPTO)

FIG. 12.



10/11

THIS PAGE BLANK (USPTO)

13/14

[illegible]

THIS PAGE BLANK (USPTO)

FIG 1A

1A/1A

Enhancers found from the Toxics Library	
Name	known pharmacological activity
Clozapine	Serotonin Uptake Inhibitor
6-Nitroquinoxaline	Serotonin Uptake Inhibitor
Fluvoxamine	Serotonin Uptake Inhibitor
Methiothepin	5HT _{1,2} antagonist
5-Nonyloxytryptamine oxalate	5HT _{1B} agonist
N-Desmethyldiazepam	5HT _{2C} antagonist
3-Methoxycarbonylamino-b-carboline	benzodiazepine receptor inhibitor
7-(Dimethylcarbamoyloxy)-6-phenylpyrrolo	benzodiazepine receptor inhibitor
Nimodipine	Ca channel blocker
CP 55,940	cannabinoid agonist
WIN 55,212-2	cannabinoid agonist
WIN 64338	cannabinoid agonist
HU 210	cannabinoid agonist
Bromocriptine	D ₂ agonist
1-(2-Benzob[thienyl]-N-butylcyclohexanamine	dopamine uptake inhibitor
1-[1-(2-Benzob[thienyl]cyclohexyl)pyrrolidine	dopamine uptake inhibitor
2-Amino-4-methylpyridine	INOS inhibitor
17-ODYA	leukotylene B ₄ hydrolase inhibitor
Etozolate	PDE4 inhibitor
cis-(R)-N-Methyl-N-[2-(3,4-dichlorophenyl)-N-exo-Bicyclo[2.2.1]hept-2-yl-N'-(2-iodophenyl)-	sigma receptor ligand (haloperidol sensitive)
L-732,138	substance P receptor antagonist
Cyclosporin A	Calcineurin phosphatase activity inhibitor
Dioctanoylglycerol	diacyl glycerol kinase inhibitor
LY 225910	CCKB receptor antagonist
a-NETA	choline acetyl transferase inhibitor
4-Naphthalimidobutyric acid	aldose reductase inhibitor
Ergotamine	antimigraine oxytocic

THIS PAGE BLANK (USPTO)